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I. ABSTRACT 
 
MONOCYTE AND MACROPHAGE APOPTOSIS AND ACTIVATION 
DURING HIV-1 INFECTION AND ANTIRETROVIRAL THERAPY 
Sean C. Patro 
Dr. Luis J. Montaner 
 
Monocytes and macrophages represent a cell lineage integral to multiple aspects 
of HIV-1 infection, dissemination, and pathogenesis. They also play a 
fundamental role in innate host defense and may act as a tissue-privileged viral 
reservoir during all stages of infection. In the current ART-era of the HIV 
pandemic, HIV-seropositive patients can maintain undetectable viral loads for 
years. Nevertheless, this population faces central nervous system, 
cardiovascular, and other HIV-related co-morbidities, many of which are 
characterized by underlying monocyte/macrophage contributions. To investigate 
the regulation of the survival and activation profiles of monocytes/macrophages 
during HIV-1 infection in vivo, we performed the following sets of experiments: (1) 
we determined monocyte apoptosis profiles in previously uncharacterized highly 
viremic HIV (+) donors and assessed monocyte gene expression associated with 
monocyte apoptosis outcome; (2) we tested the impact of ART and CCR5 
antagonism during advanced HIV-1 infection on the reversal of 
monocyte/macrophage activation; (3) we tested the impact of the interferon 
stimulated genes (ISGs) IFI6 and IFI27 as an underlying mechanism regulating 
VI 
 
monocyte apoptosis in the context of HIV-1 infection. Our results indicate both 
constitutive and oxidative stress-induced monocyte apoptosis are elevated in HIV 
(+) individuals with viral loads above 40,000 HIV-1 copies/mL and are associated 
with decreasing CD4 count. Furthermore, elevated apoptosis is associated with a 
shift in interferon stimulated gene and Bcl-2 family gene expression. Longitudinal 
analysis of ART treatment during advanced HIV-1 infection (nadir CD4 count < 
100 cells/mm3) demonstrated differential reversal of cell-associated and soluble 
biomarkers of monocyte/macrophage activation. We show the addition of CCR5 
antagonism (Maraviroc) does not impact the reversal of monocyte/macrophage 
activation beyond the impact of standard ART alone. Finally, we investigate the 
roles of the ISGs IFI6 and IFI27 in the regulation of monocyte apoptosis in vitro. 
Our work demonstrates the impact of viral and host pressures on monocyte 
survival/apoptosis and activation state during distinct stages of HIV-1 infection. 
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CHAPTER 1: Introduction 
 
1.1 The HIV-1 pandemic: The early years, infection, and treatment 
1.2 HIV target cells: CD4 T-cells and monocytes/macrophages 
 1.2.1 HIV CD4 T-cell infection and activation 
 2.2 Monocyte heterogeneity and infection by HIV/SIV 
 1.2.3 Role of macrophages as viral reservoirs 
 1.2.4 Role of monocytes and macrophages in HIV CNS and gut 
pathogenesis 
1.3: Modulation of monocyte and macrophage apoptosis during HIV-1/SIV 
infection 
 1.3.1: SIV infection of NHP models in vivo 
 1.3.2: Monocyte regulation in HIV infection: Pro-apoptotic 
 1.3.3: Monocyte regulation in HIV infection: Anti-apoptotic 
 1.3.4: MDM HIV infection in vitro: Pro-apoptotic 
 1.3.5: MDM HIV infection in vitro: Anti-apoptotic 
1.4: Modulation of monocyte interferon gene expression during HIV-1 infection 
1.5: Cell-associated and soluble biomarkers of monocyte and macrophage 
activation during HIV-1 infection and ART 
 1.5.1: Cell Associated Biomarkers 
 1.5.2: Soluble Biomarkers 
1.6 Scope of Thesis  
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1.1 The HIV-1 pandemic: The early years, infection, and treatment 
 The earliest clinical reports of HIV in the United States occurred in the 
summer of 1981 (1, 2). Unusual presentations of Pneumocystis carinii 
pneumonia, Kaposi’s sarcoma, and other infections typically associated with 
immunosuppression were documented in previously healthy homosexual men in 
California and New York City (3-6). In September 1982, the CDC coined the term 
AIDS (acquired immune deficiency syndrome) to describe the growing epidemic 
(7). In 1983, two research groups isolated a retrovirus from AIDS patients, Robert 
Gallo and colleagues in the United States (termed HTLV-III, human T-
lymphotropic virus type III) and Françoise Barré-Sinoussi, Luc Montagnier, and 
colleagues in France (termed LAV, lymphadenopathy-associated virus) (8, 9). 
This retrovirus would become known as HIV and the etiological agents of AIDS. 
 
 The natural disease course of HIV-1 infection can be divided into three 
stages: acute, chronic, and advanced infection/AIDS (Figure 1.1 (10), Reviewed 
in (11)). Acute infection typically lasts 9 to 12 weeks and can present clinically as 
a flu-like acute retroviral syndrome. This period is characterized by peak viral 
replication, viral seeding of host lymphoid tissue, and severe CD4 depletion of 
gut-associated lymphoid tissue (12). During chronic infection, viremia is partially 
controlled by host immune responses, reaching a relatively stable viral load set-
point (13, 14). The length of chronic infection is highly variable, and viral set point 
is predictive of time to progression to AIDS (15, 16). Progression to AIDS 
(advanced infection) occurs when CD4 count decreases below 200 cells/mm3 or 
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with the onset of AIDS-associated opportunistic infections, as defined per CDC 
guidelines. 
 
Figure 1.1: HIV-1 natural disease course. 
HIV-1 viral load (red, HIV-1 copies/mL) and CD4 count (blue, CD4 T-cells/mm3) 
during untreated HIV-1 infection. The infection stages are acute, chronic, and 
advanced infection/AIDS. [10]  
 
 The first drug to treat HIV infection, azidothymidine (AZT/ZDV), was 
approved by the FDA on March 19, 1987 and belongs to the reverse 
transcriptase inhibitor class of anti-retroviral drugs, specifically a nucleoside 
reverse transcriptase inhibitor (NRTI). The current arsenal of anti-retroviral drugs 
targets multiple stages of the viral life cycle and includes reverse transcriptase 
inhibitors (nucleoside (NRTI), non-nucleoside (NNRTI), and nucleotide (NtRTI)), 
protease inhibitors, integrase inhibitors, and entry inhibitors (Table 1.1). By the 
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mid 1990s, combination therapy (multiple anti-retroviral drugs, with at least two 
from different classes) began the era of cART/HAART (combined/highly active 
anti-retroviral therapy), drastically extending the lifespan and improving prognosis 
of HIV-infected individuals. 
 
Table 1.1: HIV antiretroviral therapy (ART). 
ART drugs, abbreviations, year approved, and company sorted by class. 
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1.2 HIV target cells: CD4 T-cells and monocytes/macrophages 
 
1.2.1 HIV CD4 T-cell infection and activation 
 HIV viral particles target host immune cells expressing the receptor CD4 
and one of two co-receptors, CCR5 and CXCR4 (17). As it follows, the primary 
targets of HIV-1 infection are CD4 T-cells (CCR5/CXCR4) of the adaptive 
immune system and monocytes and macrophages (CCR5) of the innate immune 
system. 
 Depletion, activation, and dysfunction of CD4 T-cells have come to be the 
signature of HIV-1 infection (12, 18, 19). CD4 T-cell loss during HIV-1 infection is 
mediated by multiple mechanisms including cytopathic effects by viral replication, 
immune clearance of infected cells by CD8 T-cells and natural killer cells (13, 14, 
20, 21), and bystander killing of uninfected CD4 T-cells by interactions with viral 
proteins and apoptotic ligands on antigen presenting cells (Figure 1.2, Reviewed 
in (18, 22)). In addition, the activation state of CD4 and/or CD8 T-cells (defined 
by the expression of CD38 and/or HLA-DR) is associated with both disease 
progression and poor immunological response to therapy (16, 23-25). It is also 
appreciated that sustained viremia, immune activation, and exposure to microbial 
products during HIV infection leads to a state of T-cell exhaustion in both CD4 
and CD8 compartments mediated by chronic stimulation and induction of 
inhibitory ligands and receptors such as PDL-1/PDL-2-PD-1, among others (26-
28). 
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Figure 1.2: Mechanisms of CD4 T-cell death during HIV-1 infection. 
During untreated infection, CD4 T-cell death results from apoptotic pressure of 
HIV-1 proteins, activation-induced death, and extrinsic apoptosis mediated by 
death ligands, often presented by on antigen presenting cells (APC). (Adapted 
from [22].)  
 
1.2.2 Monocyte heterogeneity and infection by HIV/SIV 
 Monocytes are phagocytic cells that are generated from myeloid 
progenitors in bone marrow, circulate in blood, and migrate into tissue, maturing 
into macrophages in response to chemotactic and inflammatory signals (29). 
Blood monocytes exist in heterogeneous populations, similar in both humans and 
rhesus macaques, and much of our understanding of monocyte heterogeneity 
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and phenotypes in both healthy and HIV/SIV-infected conditions has been 
obtained from non-human primate (NHP) models (29-31). Classical monocytes 
(CD14++CD16-) represent the largest subset under normal conditions while the 
intermediate (CD14++CD16+) and non-classical (CD14+CD16++) subsets are 
expanded during HIV/SIV-infection and other inflammatory conditions (30, 32-36) 
(Figure 1.3). Separate transcriptional profiles have been described for CD16- and 
CD16+ subsets (37), and BrdU pulse-chase has demonstrated that maturation of 
monocytes in blood progresses from classical to intermediate to non-classical 
monocytes upon differentiation (29). Furthermore, the CD16+ subsets bear 
significance based on permissiveness to infection (30, 38-40) and 
immunophenotypic similarity to infected macrophages in tissue (41, 42). In light 
of such heterogeneity, subset composition and phenotype are an important 
consideration of monocyte studies regarding all stages of HIV-infection. 
 
Figure 1.3: Human monocyte subsets. 
Human blood monocytes are divided into classical (CD14++CD16-), intermediate 
(CD14++CD16+), and non-classical (CD14+CD16++) subsets by expression of 
CD14 and CD16 (left). Shown are representative HIV (-) (middle) and HIV (+) 
(right) donors.  
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  Among HIV-infected individuals (both viremic and ART-suppressed), it is 
estimated that less than 0.1% of circulating monocytes harbor HIV-1 DNA (38, 
43, 44). The degree of ongoing replication in monocytes in vivo is a source of 
debate as early studies found monocytes from HIV (+) patients could seed 
infection of PHA-stimulated PBMC co-culture in vitro (45) while more recent 
studies have proposed the hypothesis that tissue macrophages may reflect 
phagocytosed infected T-cells rather than macrophage infection (46).Additionally, 
viral sequence analysis has suggested low levels of monocyte virus production 
(38). The CD16+ subsets of blood monocytes has been proposed to be 
permissive to infection as they harbor higher levels of HIV DNA when compared 
to the CD16- fraction, explained by higher expression of CCR5 and expression of 
high molecular weight APOBEC3G (compared to restrictive, low molecular 
weight APOBEC3G in CD14+CD16- monocytes) (40). Similarly, intermediate 
monocytes are reported to have the highest levels of SIV DNA in acutely infected 
rhesus macaques (30). The most direct evidence for the importance of infection 
of CD16+ monocytes is supported by the detection of p28/p24-positive, CD16+ 
macrophages in brain of SIVE macaques and autopsy of HIVE patients (41, 47). 
 
 The resistance of monocytes to infection compared to tissue macrophages 
has been assigned to the activity of a number of host intrinsic factors and other 
mechanisms that limit infection and replication in monocytes (Figure 1.4, 
Reviewed in (48, 49)). Restriction of monocyte infection is considered to occur 
post-entry and pre-integration (50). Transcriptional profiling of monocytes 
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suggests expression of the cytidine deaminases APOBEC3G and APOBEC3A, 
which are downregulated with macrophage differentiation, may contribute to 
restriction of replication in monocytes (51). A low level of nucleotide precursors, 
limiting reverse transcription, may contribute to low infection in monocytes, 
macrophages, and dendritic cells; however, this block is removed by the 
SIV/HIV-2 accessory protein Vpx (52, 53). The restriction factor responsible for 
this activity was discovered to be the deoxynucleoside triphosphate 
phosphohydrolase SAMHD1 (54, 55). In addition to host restriction factors, 
microRNA activity may also limit HIV-1 transcription in monocytes, either directly 
targeting viral mRNA or indirectly by the repression of CycT1 (56, 57). Together, 
factors above and the recently described interferon stimulated gene (ISG) 
viperin/RSAD2 (58) limit HIV-1 infection in monocytes. 
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Figure 1.4: Barriers to HIV-1 replication in monocytes. 
Shown are intrinsic host restriction factors that contribute to restriction of HIV-1 
replication in monocytes (top left) and differences in susceptibility of select 
monocyte subsets (bottom left) and tissue macrophages (right). [49]  
 
1.2.3 Role of macrophages as viral reservoirs 
 Although macrophages are typically ascribed a secondary role compared 
to resting memory CD4 T-cells in discussions of HIV/SIV persistence and viral 
reservoirs, multiple observations over the past 20 years makes a strong 
argument for their involvement. This argument is based on evidence of 
productively infected macrophages in lymphoid tissue (59) and macrophage 
sequence evolution in AIDS patients (60). In non-human primates models, 
rhesus macaques that are severely CD4-depleted, by either natural progression 
or severely pathogenic SHIV infection, maintain high levels of viral replication 
through macrophage sources of virus (61-63). This evidence is supported by 
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studies of SIV infection with antibody-mediated CD4 T-cell-depletion, in which 
high levels of CD68+ macrophage infection are observed in rectal biopsies (64) 
and high proportions of viral RNA-positive macrophages are observed in 
lymphoid tissue and brain (65). This concept of macrophages as an immune-
privileged reservoir in various tissue sites is reviewed in (49). As noted above, 
these observations stand in contrast to recent data that suggests macrophages 
acquire viral DNA by phagocytosis of infected CD4 T-cells and therefore do not 
reflect productive infection (46). 
 
1.2.4 Role of monocytes and macrophages in HIV CNS and gut 
pathogenesis 
CNS Pathogenesis 
 Macrophage infection within the CNS has been appreciated since the 
early years of the HIV-1 epidemic, described in post-mortem HIV patients with 
CNS pathology (66, 67). SIV models have demonstrated that the virus enters the 
brain early during acute infection (41, 68) and the primary target of HIV/SIV 
infection within the brain is the perivascular macrophage (CD68+CD163+), which 
are immunophenotypically similar to expanded CD14+/-CD16+ monocytes 
observed during infection, suggesting a mechanism of CNS entry (41, 47, 69). 
This population is distinct from resident microglia and “recently infiltrated” 
macrophages (MAC387+) recruited from peripheral blood during inflammatory 
conditions (70-73). The association of monocyte activation and CNS recruitment 
with direct measurements of neuronal injury and neurocognitive dysfunction in 
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both HIV-infection and SIV-models supports a vital role of the 
monocyte/macrophage in CNS pathogenesis (Figure 1.5, Reviewed in (49, 73, 
74)). These include an expansion of activated subsets in blood and brain (32, 47, 
69, 75, 76), increased monocyte turnover in blood (71), monocyte ISG 
expression (Discussed in Section 1.4), and soluble markers of 
monocyte/macrophage activation, including sCD14 in blood (77, 78) and 
cerebrospinal fluid (CSF) (47, 79) and sCD163 in blood (80). Once virus and 
inflammatory/activated macrophages reach the brain, the cellular mechanisms of 
neuronal injury include the activity of viral proteins, activating chemokines and 
cytokines, and neurotransmitters (Reviewed in (49, 81, 82)). 
 
 
Figure 1.5: Monocytes and macrophages in HIV-1 pathogenesis. 
Shown is an overview of the contribution of monocytes/macrophages to HIV-1 
pathogenesis, including CNS, during acute, chronic, and advanced infection 
(AIDS) and ART treatment. [74]  
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Gut Pathogenesis 
 Under normal conditions, macrophages within the gastrointestinal mucosa 
are maintained in an anti-inflammatory, functionally inert state (though still 
functionally competent) despite the presence of GI bacteria through TGF-β 
production by resident stromal cells (83). This mechanism also downregulates 
CD4 and CCR5 expression conferring a resistance to HIV-1 infection in gut 
macrophages not observed in other tissue macrophages, such as vaginal 
macrophages (84, 85). However, during chronic, untreated SIV/HIV infection, gut 
epithelial barrier dysfunction results in leakage of microbial products that drive 
TLR-mediated activation and overall increases in immune activation (86-90). 
Tissue macrophage activation is proposed to be an important determinant of 
outcome as markers of plasma LPS (sCD14) predict mortality in HIV-1 infected 
individuals (91). Plasma sCD14 and markers of gut epithelial dysfunction also 
predict mortality among ART-suppressed individuals (92, 93). During chronic 
HIV-1 infection, high levels of CD68+CD163+ macrophages are recruited to gut 
mucosa by CCL2/CCR2 and integrin-β7-mediated mechanisms (94). Within gut 
mucosa, these macrophages may contribute to epithelial barrier dysfunction and 
microbial translocation by increased production of pro-inflammatory cytokines 
and chemokines (TNF-α, IL-1β, CCL5, CXCL9, CXCL10) and impaired 
phagocytic activity (88, 94). 
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1.3: Modulation of monocyte and macrophage apoptosis during HIV-1/SIV 
infection 
 Unlike CD4 T-cells, the apoptotic fate of monocytes during chronic 
infection and elevated HIV/SIV viremia is less clear, as different ex vivo and in 
vitro studies have reported both anti-apoptotic and pro-apoptotic mechanisms 
and outcomes. HIV-1/SIV can directly impact apoptosis in monocyte and 
macrophages (Figure 1.6) and monocyte/macrophage-mediated apoptosis of 
non-myeloid bystander cells, particularly CD4 T-cells (Reviewed in (18, 22)). 
 
 
Figure 1.6: Pro- and anti-apoptotic pressures on monocytes/macrophages 
during HIV-1 infection/exposure. 
Summary of apoptotic impacts of HIV-1 infection/exposure observed ex vivo and 
with infection/exposure of monocytes/MDM in vitro.  
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1.3.1: SIV infection of NHP models in vivo 
 The NHP model of SIV-infected rhesus macaques has generated 
significant insight regarding HIV-1 pressure on monocyte and macrophage 
apoptosis. Early descriptions of macrophage apoptosis (macrophages and 
microglia) within the brain were observed with CNS pathology of rhesus 
macaques infected with neurovirulent SIV (95). The ability of in vivo SIV infection 
to sensitize monocytes and dendritic cells (DC) to constitutive and receptor-
mediated apoptosis has been well-characterized (96). Interestingly, elevated 
plasma FasL (Fas ligand) observed in rhesus macaque infection was not 
observed in the non-pathogenic model of SIV infection in African green monkeys 
(AGM). Furthermore, in vivo BrdU labeling of monocytes in SIV-infection showed 
that elevated monocyte turnover is associated with macrophage apoptosis in 
lymph nodes (CD163+TUNEL+) and faster progression to AIDS (70). Elevated 
monocyte turnover has also been associated with the severity of SIV CNS 
pathology and the monocyte/macrophage activation marker, sCD163 (71). The 
association of sCD163 with monocyte turnover offers additional insight when 
interpreting monocyte/macrophage activation reflected by elevated sCD163 
during HIV-1 infection (Discussed in Section 1.4). Indeed, turnover of monocytes 
in NHP models (70, 71) may suggest a contribution of cell death and 
monocyte/macrophage dysfunction in compromised host defense during 
advanced SIV/HIV infection (97). The relationship between monocyte activation 
and soluble markers of activation during viremia and ART-mediated viral 
suppression will be addressed in this thesis.  
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1.3.2: Monocyte regulation in HIV infection: Pro-apoptotic 
 While findings in NHP models have demonstrated pro-apoptotic impacts of 
SIV-infection, in vitro studies of HIV-1 exposure/infection of monocytes and 
macrophages and ex vivo studies on monocytes from HIV-infected patients have 
yielded both pro- and anti-apoptotic findings. It is of paramount importance to 
interpret ex vivo HIV-1 monocyte apoptosis data in the context of clinical status 
(HIV-1 viral load and CD4 count). In a study of HIV-exposed seronegative (ESN), 
HIV (+), and HIV (-) individuals, Velilla et al described increased constitutive and 
in vitro HIV-1 induced monocyte apoptosis in the ESN and HIV (+) group relative 
to the HIV (-) group (98). However, viral load, CD4 count, and ART-status were 
not reported in the HIV (+) group. A study of STAT1 expression demonstrated 
elevated constitutive monocyte apoptosis and plasma TRAIL in the HIV (+) 
viremic group (off-ART, median viral load = 94,000 copies/mL) relative to the HIV 
(-) group and an association of STAT1 protein expression and monocyte 
apoptosis in the HIV (+) viremic group (99). Regarding myeloid dendritic cells 
(mDC), decreased Bcl-2 expression and increased apoptosis (Caspase-3+) was 
observed in HIV (+) (mean viral load=89,700 copies/mL) relative to HIV (-) 
donors, and apoptosis was associated with viral load CD8 T-cell activation 
(CD38+) and decreased with ART (100). Taken together, pro-apoptotic outcomes 
in monocyte studies in HIV infection have pointed to a relationship between high 
viral load and cell death. 
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1.3.3: Monocyte regulation in HIV infection: Anti-apoptotic 
 However, ex vivo HIV-1 studies have also demonstrated mechanisms of 
HIV-1 induced monocyte apoptosis resistance. Cosenza et al observed evidence 
of apoptosis resistance in HIVE-CNS, as p24+ cells had lower percentages of 
TUNEL+ cells than the overall CNS macrophage/microglia population (101). 
Furthermore, ex vivo analysis of gene expression from circulating monocytes and 
in vitro HIV-1 exposure/infection of whole PBMC supported gene modulation 
consistent with anti-apoptotic regulation (Reviewed in (102)). Specifically, a 
stable 38-gene anti-apoptosis gene signature was noted in monocytes from 
viremic HIV (+) donors (mean VL=32,000 copies/mL) compared to HIV (-) donors 
and was associated with resistance to induced apoptosis (103). Gene and 
protein expression data evidence engagement of CCR5 contributing to pro-
survival signaling (p38/ERK/MAPK) by viral envelope interactions and/or natural 
CCR5 ligands (i.e., β-chemokines). Additional investigation of target apoptosis 
gene families from the parent array confirmed the apoptosis resistance 
phenotype in monocytes of additional HIV (+) patients and demonstrated the 
contribution of elevated intracellular zinc content, zinc importer expression, 
metallothionein expression (mean VL=39,294 copies/mL) (104) and Rb1 protein 
activity (mean VL=59,269 copies/mL) (105) to HIV-1 mediated monocyte 
apoptosis resistance. These data suggest viral replication and CCR5 ligands may 
promote monocyte survival, which stands in contrast to pro-apoptotic findings 
reviewed above. The relationship between pro- and anti-apoptotic regulation of 
monocytes in HIV infection will be addressed in this thesis. 
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1.3.4: MDM HIV infection in vitro: Pro-apoptotic 
 HIV-1 infection of MDM in vitro increases sensitivity to TRAIL-mediated 
apoptosis. Recombinant TRAIL and TRAIL-receptor agonists were initially 
explored in vitro as a means of purging HIV-1 infected CD4 T-cells and 
macrophages (106). In vitro HIV-1 infection of MDM and comparison of primary 
peripheral blood lymphocytes in HIV (-) and HIV (+) donors demonstrated higher 
TRAIL-receptor expression in HIV (+) conditions, and MDM from HIV (+) donors 
(relative to HIV (-) donors) were more sensitive to recombinant TRAIL-mediated 
apoptosis. Downstream of receptor expression, HIV infection/exposure was 
shown to sensitize macrophages to apoptosis by inhibiting Akt-1 activity in the 
Akt-1-FOXO3a pathway (107, 108). Furthermore, Laforge et al provided an 
extensive in vitro characterization of HIV-1 induced monocyte and dendritic cell 
apoptosis sensitization (96). Infection of MDM increased both activation induced 
(LPS+IFN-γ) and ligand mediated apoptosis (TRAIL) by the down-regulation of 
the anti-apoptotic molecules FLIP and Mcl-1 and up-regulation of the pro-
apoptotic Bax and Bak. Similarly, Zhu et al demonstrated infection with a HIV-
pseudotype sensitized MDM to TRAIL-mediated apoptosis by down-regulation of 
the TRAIL decoy receptors DcR1 and DcR2 (TNFRSF10C and TNFRSF10D) 
and the anti-apoptotic protein FLIP (109). Additionally, the accessory protein Vpr 
has been shown to induce apoptosis in monocytes in vitro (110, 111). 
 
 In vivo and in vitro evidence has accumulated of HIV-induced TRAIL (both 
membrane and soluble) production by monocytes and macrophages as a 
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mechanism of bystander apoptosis induction. In a study of 107 HIV (+) 
individuals, sTRAIL was elevated in viremic and suppressed patients relative to 
HIV (-) donors, and sTRAIL and mTRAIL was highly inducible in monocytes in 
vitro in a CD4-dependent mechanism by a type-I interferon/STAT pathway (112). 
The ability of HIV-infection and type-I interferons to induce MDM sTRAIL/mTRAIL 
has been further characterized to be IRF-1/IRF-7-dependent (113). Finally, Kim 
et al demonstrated robust TRAIL induction in MDM in pathogenic infection 
settings (SIV-RM in vivo, HIV in vitro) but not in non-pathogenic systems (SIV-
chimpanzee, SM, AGM), suggesting a TRAIL-mediated role of monocytes and 
macrophages in CD4 T-cell depletion (114). Overall, induction of apoptosis after 
MDM infection is primarily associated with external regulation of activation 
(TRAIL, LPS, IFN-γ). 
 
1.3.5: MDM HIV infection in vitro: Anti-apoptotic 
 One the other hand, anti-apoptotic impact has been demonstrated by 
infection and HIV-1 proteins in vitro, including Tat, Nef, and Env (115-117) 
(Reviewed in (118, 119)). This impact is complimented by the notion that viral or 
disease pressures that drive monocyte activation and/or differentiation mediate 
an increasingly pro-survival phenotype (110, 120-125). Specifically, Zhang et al 
demonstrated HIV-1 infection of MDM resulted in increased Bcl-2 expression, 
and treatment with exogenous HIV-Tat (126) was able to recapitulate apoptosis 
resistance to TRAIL-mediated apoptosis (127). Furthermore, it was demonstrated 
that HIV-Nef could mediate apoptosis resistance in MDM, mediated by Bad 
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inactivation by hyper-phosphorylation (128). HIV-1 infection of MDM was also 
described to upregulate anti-apoptotic Bcl2 and Bcl2L1 and downregulate Bad 
and Bax, the former through a TNF-α-dependent mechanism (129). HIV-induced 
M-CSF production has been implicated in monocyte/macrophage-associated 
pathogenesis (Reviewed in (130)). Specifically, Env expression induced an anti-
apoptotic macrophage state, characterized by increased Mcl-1 and Bcl2-A1 
expression and decreased TRAIL-R1 expression by a M-CSF dependent 
mechanism (131). Additionally, as noted above, in vitro engagement of CCR5 by 
virus can mediate Rb1 protein activity resulting in apoptosis resistance (103, 
105). Interestingly, osteopontin, elevated during SIVE, also protects human 
monocytes from induced apoptosis in vitro (132). Overall, apoptosis resistance is 
primarily associated with virus/receptor interactions, intrinsic, and/or paracrine 
regulation. 
 
1.4: Modulation of monocyte interferon gene expression during HIV-1 
infection 
 The predominance of ISG expression in monocytes and macrophages is a 
hallmark of HIV-1 infection and has been well described in both in vitro studies 
and patient populations spanning all stages of infection. 
 
 Early studies demonstrated elevated plasma interferons in HIV-1 infected 
patients during both acute (133) and advanced (134) infection as well as the 
impact of ART on plasma IFN-α (135). Additionally, plasma IFN-α has been 
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associated with plasma LPS (but not viral load), suggesting that microbial 
translocation may serve as a source of sustained type-I interferon-driven 
activation (86). Monocyte ISG expression in the context of HIV-1 exposure or 
infection has been demonstrated both ex vivo and in vitro. Early studies 
established HIV-1 treatment of monocytes could induce IFN-α production 
independent of productive infection (136). Microarray studies have extensively 
characterized ISG induction from HIV-1 infection/exposure of MDM in vitro, (113, 
137-140), temporal phases of ISG induction (138, 139), and an overlap of type-I 
ISG expression profiles between patient derived monocytes and in vitro 
stimulated monocytes (140). Additionally, the HIV-1 accessory proteins Tat and 
Vpr are independently sufficient to induce ISG expression in MDM in vitro (141, 
142). Microarray and gene expression studies of primary patient monocytes have 
also demonstrated robust ISG expression during chronic infection associated 
with viremia (140, 143-146) that is decreased with viral suppression (147). ISG 
expression has also been characterized relative to infection stage in human 
lymphoid tissue in a cross-sectional study (148) and longitudinally in PBMC in the 
SIV NHP model (149). 
 
 This ISG profile is further supported by the detection of ISGs at the protein 
level, including both monocyte/macrophage cell-associated and plasma soluble 
proteins. Plasma CXCL10 is a well-characterized marker of ISG expression 
during HIV-1 infection, as it is elevated in viremic patients (144, 146, 150-152) 
and associated with HIV-1-associated neuronal injury (144, 146) in a manner 
22 
 
similar to monocyte ISG expression (145). Additionally, ex vivo culture of 
duodenal tissue, enriched for macrophage infiltrate in viremic HIV (+) donors, has 
demonstrated elevated CXCL10 production relative to tissue from HIV (-) donors 
(94). Longitudinal studies have described increased plasma CXCL10 during STI 
(scheduled treatment interruption) (153) and decreased CXCL10 during ART 
(135); however, cross-sectional studies suggest viremic suppression is not 
accompanied by complete reversal, as plasma CXCL10 is elevated in ART-
treated patients (150, 152) and elite controllers (152) relative to HIV (-) donors. 
CD169 (Sialoadhesin, SN, SIGLEC1) is a surface-expressed ISG (IFN-α, IFN-γ 
inducible) on monocytes, macrophages, and dendritic cells and is highly 
expressed during HIV-1 infection (143, 146, 154-156) and other inflammatory 
diseases (155, 157). CD169 can facilitate trans-infection of target cells by both 
monocytes and dendritic cells (156, 158, 159). CD169 expression was elevated 
in progressive stages of infection a HIV-1 cross-sectional study (154) and 
reversed with ART in a SIV longitudinal study (160). 
 
 Monocyte/macrophage ISG expression also has a significant bystander 
effect on T-cells and other immune cells. As noted above, ex vivo and in vitro 
studies suggests HIV-1 can induce monocyte/macrophage TRAIL expression 
(membrane and soluble) by an IFN-dependent mechanism that may contribute to 
bystander CD4 T-cell apoptosis (22, 112, 113). Monocyte/macrophage ISG 
expression may also play a role in T-cell exhaustion during HIV-1 infection. 
Specifically, the ligands, PD-L1 and PD-L2 are expressed on monocytes and 
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macrophages during HIV-1 infection and can be up-regulated by factors present 
during infection including virus particles, TLR-agonists, and type-I interferons (27, 
28, 161) (Reviewed in (162)). PD-L1/L2 ligand interactions with PD-1 on 
activated T-cells can mediate CD4 and CD8 T-cell exhaustion during HIV-1 
infection (26, 27, 163). Finally, type-I interferon driven BAFF (B cell-activating 
factor) expression and secretion by monocytes may also drive B-cell dysfunction 
observed during HIV-1 infection (164). 
 
 While ISG expression is associated with disease progression in HIV/SIV 
infection (165, 166), ISGs also include HIV restriction factors that inhibit/limit 
replication in monocytes (48, 49, 167, 168). While comprehensive study is not a 
focus of this thesis, we will briefly highlight major HIV-1 restriction factors 
described to date. The APOBEC3 family of cytidine deaminase hypermutates 
incoming HIV proviral DNA (169), and SAMHD1 limits the pools of dNTPs 
available for reverse transcription (54, 55). IFITM proteins (IFITM1-3), members 
of the ISG12 family, have also been shown to inhibit HIV replication (170). 
Tetherin (BST2, CD317) restricts budding of virus particles (171). Finally, Mx2 
has recently been ascribed post-entry/pre-integration restriction activity (172). 
The overall benefit (HIV restriction) or burden (association with disease 
progression and persistence by PD-L1/IL-10 (27, 161, 173)) of ISG expression 
remains in debate. This thesis will address whether ISG induction in monocytes 
relative to viral load is related to changes in monocyte apoptosis. 
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1.5: Cell-associated and soluble biomarkers of monocyte and macrophage 
activation during HIV-1 infection and ART 
 It is established that sustained T-cell activation during HIV-1 infection is 
associated with disease progression and sub-optimal CD4 T-cell recovery after 
ART (16, 23-25). Nonetheless, the significance of monocyte and macrophage 
activation, independent of infection, has returned to prominence due to the 
association with gut epithelial barrier dysfunction and microbial translocation (77, 
86-89, 91-93, 174, 175). The phases of this activation sequela, gut barrier 
dysfunction (apoptosis, I-FABP, zonulin) (91-93), microbial translocation (plasma 
LPS, plasma 16S rDNA) (77, 86, 87, 91, 174, 175), and biomarkers of innate 
activation (sCD14) (77, 78, 86, 91, 174, 175), have been investigated for their 
association with one another and predictive value of clinical and therapeutic 
outcome. Furthermore, activation of monocytes and macrophages (by virus, 
microbial translocation, immune cross-talk, and other sources) remains a 
potential source of inflammation that may not be fully reversed during ART 
(Figure 1.7) (80, 86, 91, 150, 174, 176-179). We will address the relationship 
between markers of innate monocyte/macrophage activation and ART-mediated 
viral suppression in advanced infection. 
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Figure 1.7: Biomarkers of monocyte and macrophage activation during HIV-
1 infection. 
Shown are major cell-associated biomarkers of monocyte/macrophage activation 
during SIV/HIV-1 infection.  
 
1.5.1: Cell Associated Biomarkers 
 The expansion of CD16+ monocyte subsets, including CD14++CD16+ 
intermediate monocyte subset, has been described during HIV-1 (32-36) and SIV 
viremia (30) and are associated with HIV pathogenesis (32, 47, 150). Elevated 
CD16+ monocyte subsets may indicate long-term inflammation as similar 
elevations have been described in patients with cardiovascular disease in HIV (-) 
(35) and ART-suppressed cohorts (180). CD14++CD16+ monocytes are also 
elevated in elite controllers compared to HIV (-) controls, supporting evidence of 
ongoing innate activation despite viral control (181). Regarding ART, the 
intermediate monocyte subset was decreased in patients treated during early 
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infection, but not chronic infection (177), and cross-sectional comparisons have 
demonstrated suppressed patients reach comparable levels to HIV (-) donors 
(35). 
 
 CD163, the hemoglobin/haptoglobin receptor, is expressed on blood 
monocytes tissue macrophages (182) and can be shed, as sCD163, by 
ADAM17/TACE-cleavage during activated/TLR-stimulated conditions (177, 183). 
CD163 expression is increased on intermediate monocytes of HIV (+) individuals 
(31) and is highly expressed on macrophage infiltrates of CNS, cardiac, and gut 
tissue during HIV/SIV infection (69, 72, 94, 184). 
 
1.5.2: Soluble Biomarkers 
 Soluble biomarkers of monocyte/macrophage activation are also well-
characterized during HIV infection, including sCD14 and sCD163. Elevated 
sCD14 has been described as a marker of HIV-associated microbial 
translocation and increased plasma LPS (86, 152, 185). Longitudinal ART 
studies have found elevated sCD14 levels persist despite viral suppression (86, 
174, 177) and are only partially resolved after extended ART (174, 175). In 
addition, cross-sectional comparisons have demonstrated ART patients do not 
resolve sCD14 to the level of HIV (-) donors (91, 152, 174, 178, 179). 
 
 Soluble CD163, shed from activated monocytes and macrophages, is 
elevated during SIV/HIV infection and associated with both cardiac and CNS 
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pathogenesis (36, 71, 80, 150, 152, 176, 177, 179). Soluble CD163 was reduced 
to HIV (-) levels in patients treated during early infection but not in those treated 
during chronic infection (177); however, unlike the intermediate monocyte subset, 
cross-sectional studies suggest sCD163 does not reach levels of HIV (-) donors 
upon viral suppression (80, 150, 176, 179). 
 
 The relationship between monocyte subsets, viral load, monocyte 
apoptosis, soluble markers of activation, and ART-mediated viral suppression will 
be addressed in this thesis. 
 
1.6 Scope of Thesis 
 This thesis provides new data on monocyte biology during HIV-1 infection 
addressing regulation of monocyte apoptosis, innate immune activation, viral 
load, and ART-mediated viral suppression. We investigate the presence of 
activated monocyte subsets in patients with high viral load/low CD4 count and 
examine modulation of monocyte apoptosis sensitivity and transcription profiles 
(ISG expression) relative to viral load/CD4 count. We characterize the induction 
of genes associated with apoptosis regulation as well as the impact of over-
expression of target genes on apoptotic outcome in vitro. Additionally, we 
investigate the impact of ART-mediated viral suppression on 
monocyte/macrophage activation profiles in HIV-1 patients initiating therapy 
during advanced HIV-1 infection (CD4 count less than 100 cells/mm3). We also 
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investigate the impact of CCR5 antagonism during ART on the reversal of 
monocyte/macrophage activation profiles. 
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ISG/Bcl2 family gene expression in HIV-1 infected 
patients during chronic infection 
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2.1 Introduction 
 While HIV-1 infection is characterized by compromised adaptive immunity 
with CD4 T-cell loss in tissue (12) and peripheral blood (18, 19), the loss of 
monocytes and macrophages is less evident. The impact of HIV-1 viremia on 
monocyte gene expression (103, 140, 147, 161, 186) and function (32, 33, 40, 
143, 153) is largely independent of productive infection, as less than 0.1% of 
circulating monocytes are estimated to harbor integrated HIV-1 DNA (38, 43, 44). 
However, exposure to viral particles and proteins, microbial products, and host 
products (inflammatory cytokines) can modulate monocyte function (27, 102, 
140, 147, 158, 161, 187) and apoptosis (96, 99, 103, 109, 127, 131) during HIV-1 
infection. 
 
 Unlike CD4 T-cells, the apoptotic fate of monocytes during elevated 
HIV/SIV viremia is less clear, as ex vivo and in vitro studies have reported both 
anti-apoptotic (103-105, 127, 131) and pro-apoptotic (96, 99, 109) mechanisms 
and outcomes (Figure 1.6, Section 1.3). Gene expression studies have identified 
a predominant anti-apoptosis gene signature in monocytes during chronic HIV-1 
infection (103), and multiple studies have described anti-apoptosis mechanisms 
ex vivo and in vitro including: engagement of CCR5 and pro-survival signaling 
(p38/ERK/MAPK) (103), elevated intracellular zinc content, metallothionein 
expression (104), elevated Rb1 protein activity (105), and M-CSF mediated 
protection from TRAIL-induced apoptosis (131). Based on oxidative stress (188) 
and increased expression of apoptotic ligands (22, 112, 113) observed during 
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HIV infection, resistance to apoptosis has been tested by multiple induction 
mechanisms (CdCl2, sFasL) in cross-sectional studies (103-105, 131). By 
contrast, NHP SIV studies have characterized longitudinal changes under high 
viremic settings and have shown higher monocyte turnover and elevated 
activation markers in animals with rapid disease progression and 
neuropathogenesis (69-71, 73, 75), suggesting a shift in monocyte viability upon 
the onset of advanced infection. Other SIV and in vitro HIV-1 studies have 
demonstrated pro-apoptotic outcomes of viral exposure based on modulation of 
Bcl2 family genes (Bax, Bak, Mcl-1), downregulation of anti-apoptotic c-FLIP 
proteins, and downregulation of TRAIL decoy receptors (96, 109). While the 
impact of elevated viremia on monocyte activation has been characterized, no 
HIV-1 study, to date, has measured monocyte apoptosis concurrently with 
monocyte/macrophage activation to identify functional changes relative to one 
another and elevated viral load. In addition, reports on anti-apoptotic outcomes in 
monocytes from HIV-1 patients ex vivo have examined a limited range of viral 
load (mean viral load, 32,000, 39,294, and 59,269 HIV-1 copies/mL for (103-
105)), requiring a more extensive analysis across a wider viral load distribution. 
 
 Herein, we reconcile data between independent reports of pro- and anti-
apoptotic gene expression and apoptosis outcomes by the ex vivo 
characterization of circulating monocytes from a broad clinical spectrum of HIV-1 
viremia in the absence of anti-retroviral therapy. 
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2.2 Ex vivo HIV (+) monocyte apoptosis characterization and RNA 
sequencing 
 
2.2.1 Pilot RNA sequencing 
 A pilot experiment was designed to utilize RNA sequencing in isolated 
CD4 T-cells and monocytes from viremic HIV-1 patients to investigate gene 
expression in order to confirm and expand upon previous microarray findings 
(Reviewed in (102)). Apoptosis characterization and RNA-sequencing was 
performed on two samples of each HIV (-), HIV (+) LVL (low viral load), and HIV 
(+) HVL (high viral load) group (Table 2.1). (LVL and HVL defined below/above 
100,000 HIV-1 copies/mL in pilot.) Patients with low viral load were selected to 
match previously reported profiles of monocyte apoptosis resistance in chronic 
HIV (+) individuals (103-105). Patients with high viral load were chosen to the 
investigate the unstudied monocyte apoptosis and gene expression profiles in 
patients with viral load > 100,000 HIV-1 copies/mL. 
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Table 2.1: Pilot donor characteristics. 
Study group, viral load (and log viral load), and CD4 T-cell count of pilot study 
cohort.  
 
 Gene expression was examined in pooled samples of two donors from 
each group. The CD4 T-cell expression profile was not available in the HVL 
group due to low CD4 T-cell recovery. The sequencing analysis pipeline and 
read-purity is shown for each group, and mRNA reads represented 79-83% of 
the sequences (Figure 2.1). Sequencing analysis was used to highlight candidate 
genes regulating monocyte apoptosis (ISG/Bcl2 family) at different levels of HIV-
1 viremia (Pursued in Sections 2.2.2, 2.2.3, and 2.3). 
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Figure 2.1: RNA sequencing analysis. 
Shown is RNA sequencing analysis (A) and quality control/read purity (B) of the 
two CD4 T-cell and three monocyte sequencing groups.  
 
 We targeted ISG expression as a set of genes expected to be induced in 
monocytes from high viral load patients. Indeed, the HVL (+) monocytes 
demonstrated the expected ISG induction, including Mx1, IFITs, OAS1, etc 
(Figure 2.2, green box). Additionally, we observed differences in monocyte 
p53/Bcl2 family gene expression, with a predominance for pro-apoptotic gene 
expression at high viral load, and selected candidate genes for follow-up in an 
expanded cohort (Figure 2.3; Follow-up Section 2.3). 
  
36 
 
 
Figure 2.2: Interferon stimulated gene expression during HIV-1 infection. 
ISG expression profile of monocytes (left three columns) and CD4 T-cells (right 
two columns) from HIV (-) and HIV (+) (low and high viremia) individuals.  
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Figure 2.3: Monocyte apoptosis-related gene expression during HIV-1 
viremia. 
Apoptosis-regulatory gene expression profiles in monocytes of HIV (-) and HIV 
(+) (low and high viremia) individuals. Pro-apoptotic genes designated with red 
arrow, anti-apoptotic genes designated with green arrow.  
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2.2.2 Ex vivo expression of the ISG12 family highlights candidate 
ISG/apoptosis-regulatory genes 
 A primary goal of the RNA sequencing pilot was to highlight gene targets 
that may regulate apoptosis in monocytes during HIV-1 infection. The 
ISG12/FAM14 family was a lead of particular interest. This family is a group of 
small, hydrophobic, interferon-inducible proteins, upregulated during viral 
infection, with roles in both apoptosis regulation and virus-host interactions 
(Reviewed in (189, 190)). IFI6 (G1P3, ISG6-16) has demonstrated inhibition of 
mitochondrial-associated apoptosis in cancer cell lines (191, 192). Two other 
members of the ISG12 family, IFI27 (ISG12) and IFITM2 (I-8D), have 
demonstrated pro -apoptotic properties, mitochondrial localization, and induction 
during viral infection (193-195). Interestingly, IFITM2 (along with IFITM1, IFITM3) 
has been described to inhibit HIV-1 infection (170) and other viral infections 
(196). The RNA sequencing expression illustrates that the ISG12 family is highly 
expressed in the HIV (+) patient groups relative to the HIV (-) group like the 
prototypic ISG, Mx1 (Figure 2.4). Of note, expression of the pro-apoptotic IFI27 
expression was elevated in the HVL (+) group (relative to HIV (-)) by over 1000-
fold. Based on elevated expression in the pilot dataset and reported apoptosis-
regulatory function, we selected candidate ISG12 genes to characterize gene 
regulation in vitro and gene expression in an expanded HIV (+) patient cohort. 
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 Figure 2.4: Monocyte ISG12 gene family expression during HIV-1 viremia. 
Expression values of the prototypic ISG, Mx1, and the ISG12 gene are shown for 
HIV (-) (blue), HIV (+) LVL (green), and HIV (+) HVL (red). (n=2 patient per 
group) (RPKM=Reads Per Kilobase of transcript per Million mapped reads)  
 
2.2.3 In vitro regulation of IFI6 and IFI27 expression in primary human 
monocytes 
 Based on the ISG expression in HVL (+) monocytes, we first investigated 
the regulation of the apoptosis-regulatory ISG12 genes, IFI6 and IFI27, in 
primary human monocytes by IFN-α and HIV-1 treatment in vitro. IFI6 and IFI27 
were robustly induced after 48 hours incubation with high-dose exogenous IFN-α 
(0 to 5000 units/mL) (Figure 2.5, left column). IFN-α treatment induced a 2-log 
fold induction for IFI6 (similar to Mx1) and a 4-log fold induction for IFI27 over 
unstimulated conditions (Figure 2.5E). We also investigated induction at lower 
levels of stimulation (0 to 50 U/mL) (Figure 2.6, right column) and observed IFI6 
expression at very low doses (1-10 U/mL) (Figure 2.5B) and comparable IFI6 and 
IFI27 raw expression at 25 to 50 U/mL (Figure 2.5B, D, representative of n = 2). 
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Figure 2.5: Dose response of IFI6 and IFI27 expression in primary 
monocytes. 
Primary monocytes were treated with high-dose (0-5000 U/mL) (left) or low-dose 
(0-50 U/mL) (right) IFN-α for 48 hours and gene expression was measured by 
RT-PCR. Expression of IFI6 (A, B) and IFI27 (C, D) are shown. Fold-induction 
over unstimulated (E, F) is shown for Mx1 (blue), IFI6 (red), and IFI27 (green).
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Figure 2.6: Kinetics of IFI6 and IFI27 expression in primary monocytes. 
Primary monocytes were treated with high-dose (500 U/mL) (left) or low-dose (10 
U/mL) (right) IFN-α for 72 hours and gene expression was measured by RT-
PCR. Expression of IFI6 (A, B) and IFI27 (C, D) are shown. Fold-induction over 
baseline (E, F) is shown for Mx1 (blue), IFI6 (red), and IFI27 (green).  
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 Appropriate temporal regulation of IFI6 and IFI27 expression may be 
essential for a concerted antiviral response. We conducted a 72 hour time course 
of gene expression at two IFN-α doses (10 and 500 U/mL) (Figure 2.6). IFI6 
expression peaked early, at 4 hours in the low-dose titration (Figure 2.6A) and 
14-26 hours in the high-dose titration (Figure 2.6B), while IFI27 expression 
persisted for 48 hours or longer post-stimulation (Figure 2.6C, D). Our findings 
suggest IFI6 may be upregulated with lower stimulation (Figure 2.5B) and at 
early time points (Figure 2.6A, B) compared to IFI27, which is highly expressed 
with strong IFN-α stimulation and persistent at later time points in vitro (Figure 
2.5C, Figure 2.6C, D), supporting a sequential regulation of ISG12 family 
expression (190). 
 
 We then tested whether or not HIV-1 exposure would induce IFI6 and 
IFI27 expression in monocytes similar to that of exogenous IFN-α treatment 
(Figure 2.7). The experiment was designed to test the impact of exposure (and 
limit productive infection) with monocytes cultured in the absence of 
differentiating cytokines and in Teflon pots to prevent adherence-induced 
differentiation. Monocytes were cultured for 48 hours and treated with IFN-α (500 
U/mL), HIV-1 Bal, a lab-adapted CCR5-tropic lung isolate (50 ng p24/mL), HIV-1 
Jago, a primary CCR5-tropic CSF isolate (50 ng p24/mL), and IFN-α plus HIV-1 
combinations. HIV-1 Bal induced IFI6 and IFI27 to levels slightly lower than IFN-α 
alone (Figure 2.7A, B) while HIV-1 Jago did not induce comparable ISG 
induction. Interestingly, the combination of HIV-1 Bal and IFN-α induced IFI27 
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expression one log higher than IFN-α alone, suggesting a potential additive or 
synergistic induction. Such conclusions are limited due to the lack of replicates 
and detailed follow-up; however, these data and pilot experiment data (Section 
2.2.2) suggest HIV-1 can upregulate monocyte ISG12 family gene expression 
and support follow-up in a comprehensive HIV (+) viremic cohort. 
 
 Figure 2.7: Monocyte IFI6 and IFI27 expression is induced by HIV-1 Bal, but 
not Jago in vitro. 
Primary monocytes were treated with IFN-α (500 U/mL), HIV-1 Bal or Jago (50 
ng p24/mL), or a combination of IFN-α and HIV-1 for 48 hours gene expression 
was measured by RT-PCR. Expression of IFI6 (A) and IFI27 (B) are shown. Fold-
induction over baseline (C) is shown for Mx1 (blue), IFI6 (red), and IFI27 (green).  
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2.3 Shift in monocyte apoptosis with increasing viral load and change in 
apoptosis-related ISG/Bcl2 family gene expression in HIV-1 infected 
patients during chronic infection 
 
2.3.1 Monocyte apoptosis is elevated in HIV-1 patients with high viremia 
 Constitutive and induced monocyte apoptosis were examined in a cohort 
of viremic patients (Table 2.2, 2.3) that included a wide range of viral load (2,243-
1,355,998 copies/mL) and CD4 count (26-801 cells/mm3). As expected, CD4 
count was negatively associated with viral load (P = 0.0012, R = –0.5255). Flow 
cytometry gating is shown in Figure 2.8. 
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Table 2.2: HIV (+) patient population. 
Gender, age, log viral load, and CD4 T-cell count are shown (n=35).  
 
 
 
 
Table 2.3: Gender and age of study groups. 
Gender and age distribution of HIV (-) and HIV (+) sub-groups. *Age information 
in the HIV (-) group available for 22/23 donors. 
ID# Gender Age 
Log Viral Load 
(copies/mL) 
CD4 Count 
(Cells/mm
3
) 
1 M 46 5.44 26 
3 M 23 4.97 773 
4 M 44 3.35 801 
5 M 33 5.67 380 
7 M 48 3.72 209 
8 M 33 4.38 428 
9 M 52 4.93 497 
10 M 37 3.97 620 
11 M 40 6.13 61 
12 M 41 4.56 425 
13 M 54 3.96 483 
14 M 56 5.64 27 
15 M 40 5.49 264 
16 M 27 5.18 202 
17 M 49 4.31 289 
18 M 24 4.18 653 
19 M 27 5.54 99 
20 M 43 4.61 329 
22 M 56 4.59 293 
23 M 24 4.85 464 
24 M 22 4.15 370 
25 M 60 5.45 107 
26 M 30 4.64 605 
27 F 52 4.41 142 
28 M 47 5.00 333 
29 M 52 5.07 133 
30 F 49 4.58 309 
31 M 45 4.61 163 
32 F 47 5.29 101 
33 M 36 4.64 617 
34 M 28 4.62 515 
35 M 27 4.10 325 
36 M 24 5.04 225 
37 F 84 4.29 190 
40 M 44 5.76 186 
Median 
 
43 4.64 309 
IQR 
 
30-49 4.31-5.29 163-464 
 1 
Category n Female/Total % Female Age (Med, IQR)
HIV(-) 33 8/33 0.242 43.5 (28.5-54)*
HIV(+) Lo (<Log4.6) 14 3/14 0.214 46 (30-53)
HIV(+) Hi (>Log4.6) 21 1/21 0.048 40 (27.5-47)
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Figure 2.8: Monocyte subsets and apoptosis gating. 
(A) PBMC gated on singlets, intact cells, monocyte scatter profile, and 
CD14/CD16 into non-classical (CD14+/CD16++), intermediate (CD14++/CD16+), 
and classical (CD14++/CD16-) monocyte subsets. (B) Negatively purified 
monocytes gated on singlets and intact cells and quantified for apoptosis by 7-
AAD and active caspase-3 staining.  Percent apoptotic cells counted as total 
caspase-3 positive cells (top right and bottom right quadrants).  
 
 Both constitutive and oxidative stress-induced apoptosis (20 μM CdCl2) 
(197-200) (measured by active caspase-3) were elevated in monocytes from 
patients above 40,000 (Log104.60) copies/mL (constitutive P = 0.0034, induced P 
= 0.0002) when compared to lower viremic patients (Figure 2.9, 2.10A). Based  
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Figure 2.9: Monocyte apoptosis characterization. 
Representative 7-AAD/caspase-3 dot plots of monocytes from uninfected and 
HIV(+) (14,000 and 439,508 copies/mL) individuals. Plots represent overnight 
constitutive apoptosis (first row) and oxidative stress induced apoptosis (20 μM 
CdCl2) (second row).  
 
on the analysis of the primary variable, monocyte apoptosis, HIV (+) patient 
variables are presented below and above a viral load cutoff of 40,000 HIV-1 
copies/mL (Log104.60). Irrespective of viral load, increased T-cell apoptosis was 
observed in all HIV (+) patients as compared to uninfected donors (data not 
shown). Across all HIV (+) patients, constitutive and induced apoptosis were 
positively associated with viral load (P = 0.0256, R = 0.3883 and P = 0.0002, R = 
0.5974, respectively) and inversely associated with CD4 count (P = 0.0128, R = –
0.4288 and P = 0.0464, R = –0.3491, respectively) (Figure 2.10B, 2C). 
Supporting a threshold effect of viral load, the correlation of viral load with 
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apoptosis was not present if restricting to only patients above or below 40,000 
copies/mL (all P values > 0.05, data not shown). Our data show higher HIV-1 
viral load is associated with increased constitutive and induced apoptosis in 
circulating monocytes. 
 
Figure 2.10: Monocyte apoptosis is elevated in patients above 40,000 
copies/mL and associated with viral load and CD4 T-cell count. 
(A) Group-wise comparison of constitutive (left) and induced (right) apoptosis in 
HIV(-) versus HIV(+) individuals and HIV(+) patients below versus above 40,000 
(Log104.6) copies/mL. (B-C) Spearman ranked correlation of viral load (B) and 
CD4 count (C) versus monocyte apoptosis levels in HIV(+) patients. The line on 
the y-axis represents the median constitutive (8.48%) and induced (14.82%) 
apoptosis levels of the HIV(-) group. Group-wise comparison displays median 
and interquartile range using Mann-Whitney test (two-tailed) with P < 0.05 
considered significant. Spearman (two-tailed) Rho and P values displayed with P 
< 0.05 considered significant. 
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 2.3.2 Markers of innate immune activation are increased with HIV infection 
but do not associate with change in monocyte apoptosis 
 We wanted to test if observed differences in apoptosis were associated 
with monocyte/macrophage markers of activation in our cohort. Studies have 
described CD14++CD16+ intermediate monocytes (30, 32, 34, 35, 73), plasma 
sCD14 (86, 91, 151, 185), and plasma sCD163 (71, 176, 177, 201) as 
biomarkers of monocyte/macrophage activation and pathogenesis during 
SIV/HIV-1 infection. We found the CD14++/CD16+ intermediate subset and 
plasma sCD163 were elevated in the HIV (+) group compared to controls (Figure 
2.11A, columns 1, 3), but did not detect differences within the HIV (+) groups 
(Figure 2.11B) or an association between these variables with viral load (Figure 
2.11C), monocyte apoptosis (Figure 2.11D), or CD4 count (Figure 2.12A). 
Conversely, plasma sCD14 concentration was associated with viral load (Figure 
2.11C) and CD4 count (Figure 2.12A), but not monocyte apoptosis (Figure 
2.11D, P = 0.1070). Below a CD4 count of 500 cells/mm3 (Figure 2.12B), CD4 
count demonstrated a strong negative correlation with sCD14 (P < 0.0001) and 
negatively trended with sCD163 (P = 0.0657). Taken together, these data 
support the presence of monocyte/macrophage activation demonstrated by 
elevated sCD163 and CD14++CD16+ monocytes and an association of sCD14 
with viremia and CD4 count that is independent of changes in monocyte 
apoptosis with viral load. 
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Figure 2.11: Monocyte/macrophage activation in HIV (+) patient cohort. 
(A-B) Group-wise comparison of percentage of intermediate CD14++/CD16+ 
monocytes (left), plasma sCD14 (middle), and plasma sCD163 (right) in HIV(-) 
versus HIV(+) individuals (A) and HIV(+) patients below versus above 40,000 
(Log104.6) copies/mL (B). (C-D) Spearman ranked correlation of viral load (C) 
and induced apoptosis (D) versus monocyte/macrophage activation metrics. 
Group-wise comparison displays median, interquartile range (box), and range 
(whiskers) using Mann-Whitney test (two-tailed) with P < 0.05 considered 
significant. Spearman (two-tailed) Rho and P values displayed with P < 0.05 
considered significant. 
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Figure 2.12: Monocyte/macrophage activation and CD4 count in HIV (+) 
patient cohort. 
(A-B) Spearman ranked correlation of CD4 count with percentage of intermediate 
CD14++CD16+ monocytes (left), plasma sCD14 (middle), and plasma sCD163 
(right) in total HIV(+) cohort (A) and HIV(+) patients below CD4 count of 500 
cells/mm3 (B). Spearman (two-tailed) Rho and P values displayed with P < 0.05 
considered significant. 
 
2.3.3 Apoptosis-related ISG family gene expression is altered in association 
with viral load 
 Pilot and in vitro experiments (Section 2.2) highlighted candidate 
apoptosis-regulatory gene families for follow-up in an expanded HIV (+) patient 
study. We chose to investigate monocyte expression of candidate p53 (105, 202, 
203), Bcl2/cytochrome C (204-208), and ISG (170, 189-194, 196) family genes in 
viremic HIV (+) individuals (Table 2.4). RT-PCR analysis at time of isolation 
showed significantly higher Rb1 expression in the total HIV (+) group versus the 
HIV (-) group (P = 0.0100) but no association with viral load, consistent with 
reports of Rb1 contributions to apoptosis resistance (105) in circulating  
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Table 2.4: Apoptosis related p53, Bcl2/cytochrome C, and ISG family genes 
measured by absolute quantification RT-PCR.  
Gene symbol, apoptotic impact, primers, expression in HIV (-) and HIV (+) 
groups, and P for HIV (-) versus total HIV (+) group comparison.  
 
monocytes during chronic HIV-1 infection. Within the Bcl2/cytochrome C genes 
analyzed, the HIV (+) group was characterized by lower Bcl-w (P = 0.0169) and 
higher cytochrome C gene expression (P = 0.0392); however, neither gene was 
associated with viral load. In contrast, Mx1 and the apoptosis-regulatory ISG12 
members (IFI6, IFI27, IFITM2) showed higher expression in the HIV (+) group, 
and IFI27 and IFITM2 expression was elevated in the HIV (+) group above 
40,000 copies/mL relative to the HIV (+) group below 40,000 copies/mL (Figure 
2.13A). The apoptosis-related ISGs (IFI6, IFI27, IFITM2) were also positively 
associated with viral load (Figure 2.13B). Taken together, our data demonstrate a 
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shift in monocyte gene expression with HIV-1 infection and increasing viral load 
that may support modulation of apoptosis outcome. 
 
 
Figure 2.13: Monocyte ISG12 family expression is elevated in patients 
above 40,000 copies/mL and associated with viral load. 
(A) Group-wise comparison IFI6, IFI27, and IFITM2 gene expression in HIV(+) 
patients below versus above 40,000 (Log104.6) copies/mL. (B) Spearman ranked 
correlation of viral load versus monocyte gene expression. Group-wise 
comparison displays median, interquartile range (box), and range (whiskers) 
using Mann-Whitney test (two-tailed) with P < 0.05 considered significant. 
Spearman (two-tailed) Rho and P values displayed with P < 0.05 considered 
significant. 
 
2.3.4 Multivariate analysis identifies genes associated with changes in 
constitutive and induced apoptosis in HIV infection 
 Although gene expression within target gene families was correlated (p53, 
pro-apoptotic Bcl2-genes, and ISGs) (Figure 2.14), only IFITM2 was associated 
with constitutive apoptosis, indicating that single gene analysis could not a reflect 
change in both constitutive and induced apoptosis outcome. Multivariable 
stepwise regression modeling was applied to evaluate if the combination of viral  
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Figure 2.14: Gene expression correlation of p53, Bcl2, and ISG family genes 
in monocytes of HIV (+) donors. 
Spearman ranked correlation matrix of clinical parameters (brown), p53 (pink), 
Bcl2 (blue), and ISG (green) family genes, and constitutive/induced apoptosis 
(purple). Spearman test (two-tailed, unadjusted) with P < 0.05 considered 
significant (bolded/red) and Spearman Rho is displayed. (n = 30).  
 
load, CD4 count, and gene expression variables could generate a model for the 
distribution of constitutive and induced apoptosis responses observed in HIV-
infected patients. The adjusted R-squared rank method identified IFI27, IFITM2, 
Rb1, and Bcl2 expression as the best model to describe variance in constitutive 
apoptosis (P = 3.77 10-5, adjusted-R2 = 0.5983) (Table 2.5, Figure 2.15A). A 
reduction of this model showed the key variables were IFI27 and Bcl2, 
accounting for 96.4% of the adjusted R-squared. For oxidative stress-induced 
apoptosis, the model system identified log viral load, IFITM2, Rb1, and Bax 
expression (P = 5.59 10-5, adjusted-R2 = 0.5996) (Table 2.5, Figure 2.15B), with 
log viral load and Rb1 expression representing 83.1% of the adjusted R-squared. 
Taken together, the shift in functional monocyte apoptosis observed with 
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increasing viral load was associated with a multi-gene association including 
changes in Rb1, ISG, and Bcl-2 expression. 
 
Table 2.5: Multivariate analysis of monocyte apoptosis in HIV-1 viremic 
patients. 
Constitutive and induced multivariate monocyte apoptosis models with R-
squared, P value, and model gene/viral load components shown.  
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Figure 2.15: Multivariate analysis of monocyte apoptosis in HIV-1 viremic 
patients. 
Top models generated showing (fitted) versus observed constitutive (A) and 
induced (B) apoptosis by multivariate stepwise regression of clinical parameters 
and apoptosis-gene expression.  
 
2.4 Discussion, limitations, and future directions 
 Here we show for the first time that monocyte apoptosis is elevated in 
patients with greater than 40,000 HIV-1 copies/mL and negatively associated 
with CD4 count (Figure 2.10). Our data suggest that infection can modulate 
monocyte/macrophage activation, indicated by changes in CD14++CD16+ 
monocytes and sCD163, yet does not result in a rise in apoptosis until higher 
viral loads, clarifying conflicting reports of monocyte apoptosis in HIV and SIV 
infection (70, 96, 99, 103-105, 131). 
 
 Although elevated monocyte type 1 ISG expression (140, 144, 147) and 
monocyte/macrophage activation markers (30, 32, 40, 71, 73, 86, 91, 150, 151, 
176, 177, 184, 185) have been described during HIV-1/SIV infection, the present 
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study extends these findings to include elevated monocyte apoptosis at high viral 
load in spite of active mechanisms of apoptosis resistance (i.e. Rb1 expression) 
(105). Change in ISG expression and increasing sCD14 with viral load may 
evidence increasing microbial translocation, as plasma LPS was associated with 
plasma IFN-α in HIV-1 viremic patients (86) and may contribute to the shift in 
monocyte ISG expression and apoptosis induction (209, 210). 
  
 Previous studies have demonstrated elevated sCD14 in multiple HIV (+) 
cohorts (relative to HIV (-) controls) (86, 151, 177, 178, 211), and while we 
demonstrate an association with viral load and CD4 count (Figure 2.11C and 
2.12), we do not detect a significant difference between our HIV (-) and HIV (+) 
group (Figure 2.11A), which may reflect differences in sample size and the 
clinical characteristic of our HIV (+) cohort. Interestingly, others have observed 
biphasic CD163 expression on CD14++CD16+ monocyte subset relative to CD4 
count (negative correlation below, positive correlation above 500 cells/mm3) (31). 
Although we did not measure cell-associated CD163 expression, we observed a 
negative trend of CD4 count with sCD163, as well as a strong negative 
correlation of CD4 count and sCD14 in patients below 500 cells/ mm3, supporting 
these observations (Figure 2.12B). Based on these findings, we would expect 
that the reversal of monocyte/macrophage activation markers upon ART-
mediated suppression may vary qualitatively and temporally. This is supported by 
ART-mediated resolution of Rb1 protein expression (105), decreases in the 
CD14++CD16+ subset with treatment in early infection (177), persistence of 
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plasma sCD14 (177-179), and partial, but incomplete resolution of plasma 
sCD163 (150, 176, 177, 179). Longitudinal studies will be needed to establish the 
relationship between monocyte/macrophage activation, infection stage, and ART-
mediated viral suppression (Chapter 3). 
 
 In addition to the primary findings per impact of viral load, multivariable 
analysis highlighted candidate ISG and Bcl2 genes as potential contributors to 
the functional apoptosis shift when added to rising viral load (Table 2.5, Figure 
2.15). Members of the ISG12 family (189, 190) examined here, including IFI6 
(191, 192), IFI27 (193), and IFITM2 (194), have described apoptosis-regulation 
functions. Of interest, IFITM2 was the only gene associated with apoptosis 
outcome at the single gene level (Figure 2.14) and IFITM2 and Rb1 were present 
in both models (Table 2.5, Figure 2.15), supporting specific candidate roles of 
these genes as determinant of monocyte apoptosis in HIV-infected patients. The 
impact of HIV-1 on Bcl2 family-mediated apoptosis in the CD4 compartment is 
also well described (Reviewed in (22)), and the effect on non-CD4 cell types, 
namely CD8 T-cells (212), dendritic cells (100), and now monocytes, suggests a 
global impact of HIV-1 viremia and immune activation on Bcl2-mediated 
apoptosis regulation. In addition, while Rb1 can override p53-mediated apoptosis 
induction in vitro (203), it remains to be determined whether Bax and ISG12 
family expression can override anti-apoptotic Rb1 expression as suggested by 
our data. The multiple genes measured ex vivo as contributing to apoptosis 
regulation makes it highly unlikely the functional phenotype can be accounted by 
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any one gene. However, future work should determine how the described pro-
apoptotic (IFI27, IFITM2, Bax) and anti-apoptotic (IFI6, Rb1, Bcl2) proteins exert 
regulation of apoptosis when co-expressed/knocked down to defining overall 
dominance or additive effects. 
 
 Our data do not address the potential impact of age and gender on 
monocyte apoptosis (150, 151, 213). Both HIV (-) and HIV (+) groups represent 
similar gender (no more than 25% female) and age distributions, but our cohort is 
limited in the representation of females and elderly individuals (Table 2.3). Future 
studies will need to address the impact of age and gender on monocyte 
apoptosis and apoptosis-gene expression. 
 
 Although we interpret a direct role of target genes in apoptosis outcome, a 
limitation of this study is the lack of single- and multi-gene over-
expression/knockdown in monocytes to establish a role of target genes. 
Mechanism and the impact of target gene over-expression on apoptosis outcome 
are the primary objectives addressed in chapter 4. Also, while we focused on the 
relationship between apoptosis and the expression of apoptosis-regulatory gene 
families within monocytes (p53, ISG, Bcl2), our data do not exclude contributions 
by external mechanisms in vivo affecting total monocyte numbers such as de 
novo production/turnover described in SIV NHP models (70, 71) or external 
pressures such as elevated soluble-TRAIL (99, 112) and increased TRAIL-
mediated apoptosis (96, 107, 109, 113). 
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In summary, we establish a shift in monocyte apoptosis and gene 
expression in association with high HIV-1 viral load and low CD4 count, which 
may bear on mechanisms for immunodeficiency, HIV replication, and/or HIV 
reservoir retention during HIV-1 infection in vivo. 
 
2.5 Materials 
 
2.5.1 Pilot RNA sequencing and analysis 
 Aphaeresis material was obtained from HIV-seronegative (n=2) and HIV-
seropositive donors (n=4), and monocytes and CD4 T-cells were isolated by the 
University of Pennsylvania Human Immunology Core (HIC) using the RosettaSep 
kits from Stem Cell Technologies. RNA from purified CD4 T-cells and monocytes 
from pilot cohort (Table 2.1) was obtained by trizol isolation (Sigma) and pooled 
per group for analysis. Samples were Poly-A purified for mRNA and fragmented, 
cDNA was synthesized, and 175-225 base pair cDNAs were purified from 
agarose gel and sequenced in 36 base pair reads using the Illumina Genome 
Analyzer II platform. Analysis included read filtering (removing rRNA and 
mitochondrial reads) and alignment to genome and a custom-built transcription. 
The CD4 T-cell expression profile was not available in the HVL group due to low 
CD4 T-cell recovery. 
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2.5.2 Donor population 
 HIV-1 seropositive donors (n = 35, 11.4% female, median age = 43.0 
years) were recruited from the Hospital of the University of Philadelphia (HUP) 
and Philadelphia Field Initiating Group for HIV-1 Trials (FIGHT) and were not on 
therapy at the time of the single draw. Viremic patients showed a broad spectrum 
of viremia (viral load range: 2,243-1,359,041 copies/mL; CD4 range 7-801 
cells/mm3) (Table 2.7). Viral load and CD4 count are reported from the most 
recent clinical visit (at most 3 months). HIV-1 seronegative donors (n = 33, 24.2% 
female, median age = 43.5 years) were recruited from the University of 
Pennsylvania Human Immunology Core and the Wistar Donors Program (Table 
2.8). Assays data showing less than the total recruited HIV (-) or HIV (+) 
population reflect limited patient material. All participants provided informed 
consent prior to blood draw, and all protocols were approved by the institutional 
review boards of the National Institutes of Health and The Wistar Institute. 
 
2.5.3 Monocyte and CD4 T-cell isolation and characterization 
 Heparinized blood (70-200 mL) was processed within 1-3 hours of draw. 
PBMC and plasma samples were obtained using Ficoll-Paque (Amersham 
Pharmacia Biotech) gradient separation. HIV (-) and HIV (+) donor CD4 T-cells 
were obtained from the University of Pennsylvania's Center for AIDS Research 
Human Immunology Core obtained by Rosette Sep (Stemcell Technologies) 
isolation from leukapheresis-PBMC. Monocytes were isolated by negative 
selection using the Monocyte Isolation Kit II (Miltenyi Biotec, 139-091-153) with a 
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mean biological purity greater than 85%. PBMC and isolated monocytes from 
each sample were stained with CD4-V450, CD14-APC, CD16-APCH7, CD3-
PerCPCy5.5, and CD8-FITC for determination of purity, T-cell subsets, and 
monocyte subsets. All flow cytometry antibodies were purchased from BD 
Biosciences and used per the manufacturer’s instructions. 
 
2.5.4 Plasma monocyte/macrophage activation markers 
 HIV (-) and HIV (+) plasma samples were assayed by ELISA (enzyme-
linked immunosorbent assay) for sCD14 (R&D Systems) and sCD163 (Trillium 
Diagnostics), using 1:500 dilutions, according to the manufacturers’ instructions. 
Plates were read on a BioTek Synergy HT microplate reader at 450 nm with the 
appropriate wavelength corrections. 
 
2.5.5 Quantitative real-time PCR 
 Total RNA was isolated from 2-5 million cells using the RNeasy Plus II Kit 
(Qiagen) per the manufacturer’s protocol. Up to 250 ng of RNA was used with 
the iScript cDNA synthesis kit (BioRad) as instructed. Quantitative real-time PCR 
was performed in a 20 μL reaction using Power SYBR Green PCR Master Mix 
(Life Technologies) and custom designed primers (Inegrated DNA Technologies) 
(Table 2.9) using the AB 7000 Sequence Detection System. The QuantumRNA 
Universal 18s Internal Standard (Ambion) was used due to its robust and 
consistent expression across all samples. All primer sets were assayed by serial 
dilution PCR across multiple donors to allow for absolute RNA quantification by 
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the standard curve method. The mean of three replicates of each primer-sample 
pair was input in the standard curve method and normalized to the sample’s 18s 
value to generate an absolute RNA expression units value. (Expression units 
defined as relative expression value to 18s after standardization.) 
 
2.5.6 Apoptosis induction assay 
 Purified monocytes and CD4 T-cells were incubated overnight (18-22 
hours) in non-adherent conditions (monocytes in Teflon pots to prevent 
attachment) in the presence of RPMI 1680 media with 1% Penicillin/Streptomycin 
(Corning), 1% L-Glutamine (Corning), and 10% Human Serum (Gemini Bio-
Products) with or without the addition of 20 μM CdCl2 (Sigma). All staining was 
performed at room temperature (22°C). Between 500,000 and 1 million cells 
were washed and incubated with FACS wash (DPBS (Life Technologies) 
containing 3 mM NaN3 (Fisher), 1% Bovine Serum Albumin (Sigma), 5%Human 
Serum (Gemini Bio-Products)) as an Fc-receptor block. Cells were stained with 
CD3-Pacific Blue, CD14-APC and 7-aminoactinomycin D for 15 minutes. Cell 
fixation/permeabilization was performed using the BD Cytofix/Cytoperm kit per 
the manufacturer’s instructions and washed in 1  PermWash buffer. Cells were 
then stained with anti-active caspase 3-PE (BD Biosciences), washed, and 
resuspended in 300 μL 1  PermWash buffer. Apoptosis was also assayed at 
baseline isolation in select samples. Up to 100,000 events were analyzed on a 
14-color LSR II (BD Biosciences). 
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2.5.7 Flow cytometry gating and analysis 
 Flow cytometry data analysis was performed with FlowJo software 
(TreeStar) (Figure 2.9). Singlets were gated using forward scatter height and 
area. Live cells were gated, excluding debris and aggregates, with forward and 
side scatter. To characterize monocyte subsets in PBMC, monocytes were gated 
based on distinct forward and side scatter parameters and then CD14+ or CD16+ 
cells within this population. Monocytes were then divided into classical 
(CD14++CD16-), intermediate (CD14++CD16+), and non-classical (CD14+CD16++) 
subsets. In the apoptosis analysis, all events were gated on singlets, intact cells, 
and either lymphocyte or monocyte forward/side scatter parameters. Cells were 
analyzed using 7-AAD and caspase-3, and all cells in the early apoptotic and late 
apoptotic quadrants were counted when determining the percent of apoptotic 
cells within the population. 
 
2.5.8 Statistical analysis 
 All dot, box and whisker, and scatter plots were constructed and 
statistically tested using Prism 4 (GraphPad, La Jolla, CA). All group-wise 
comparisons were performed using Mann-Whitney test with p-value displayed. 
Correlations between two variables were performed using Spearman’s 
Correlation (Rho) test with P and Rho (noted as R) values displayed. All tests 
were two-sided and P < 0.05 was considered significant. The Spearman 
correlation matrix was created with JMP10 software. Based on the analysis of the 
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primary variable (monocyte apoptosis), HIV (+) patient measured variables are 
presented below and above a viral load cutoff of 40,000 copies/mL (Log104.60). 
 
2.5.9 Multivariate linear regression modeling 
 A stepwise multiple linear regression analysis was performed to model 
constitutive and induced apoptosis using the combination of clinical and gene 
expression variables. We conducted log transformation on the independent 
variables and confirmed lack of multi-co-linearity in the final models within 
independent variables by means of the variance inflation factor (VIF). The Cook’s 
distance was used in outlier detection and removal of each independent model. 
The model selection package “leaps” (Lumley and Miller 2009) in R was utilized 
to identify the best subset of clinical/gene expression parameters that predicted 
constitutive and induced apoptosis in the linear regression. The regsubsets 
function within “leaps” was used to find the best subset of predictive parameters. 
The adjusted R-squared statistic was used as the criterion for selecting the best 
model with four or less variables per total input variable size. Various diagnostic 
plots were used to check the assumptions for the multiple linear regressions 
(data not shown). Q-Q plot was used to examine normality. Residuals plot was 
used to examine the equal variance assumption. 
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3.1 Introduction 
 Persistent immune activation during HIV-1 infection is associated with 
disease progression and sub-optimal immune recovery after ART (16, 23-25). 
Ongoing viremia has been noted to promote a state of innate immune activation 
inclusive of changes in natural killer cells (179) and monocytes/macrophages. 
Activation of monocytes and macrophages has been noted as a potentially major 
source of inflammation due to mechanisms of activation that may not be fully 
reversed during ART (80, 86, 91, 150, 174, 176-179) (Reviewed in Section 1.5). 
 
 During viremia, the CD14++CD16+ intermediate monocyte subset is 
expanded in both HIV-1 (32, 34-36) and SIV infection (30) and associated with 
HIV pathogenesis (32, 47, 150, 180). The significance of this subset as a 
potential indicator of long-term inflammation is supported by similar elevations 
described in patients with cardiovascular disease (35, 180). Soluble biomarkers 
of monocyte/macrophage activation are also well-characterized in HIV disease, 
including sCD14 and sCD163. Elevated sCD14 has been described as a marker 
of HIV-associated microbial translocation and increases in plasma LPS (86, 152, 
185). Cell-associated CD163 expression and shedding (as sCD163) from 
monocytes and macrophages is also elevated during HIV/SIV infection (31, 69, 
71, 177) and associated with both cardiac and CNS pathology (36, 71, 80, 176, 
184). The relationship between innate and adaptive activation during viremia and 
the expected decrease of both on ART raises the hypothesis that reduction in T-
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cell activation would be associated with reduction in monocyte and macrophage 
activation. 
 
 ART-mediated resolution of monocyte/macrophage activation has become 
a growing area of focus due the relationship with metabolic disease and retention 
of immune activation during HIV infection (36, 47, 150, 176, 184) (Table 3.1). The 
CD14++CD16+ intermediate monocyte subset is decreased in patients treated 
during early infection, but not chronic infection (177); cross-sectional comparison 
has demonstrated that suppressed patients reach comparable levels to HIV (-) 
donors (35). Interestingly, a reduction of the intermediate monocyte subset was 
 
Table 3.1: Monocyte/macrophage activation during ART. 
Study type, sCD14 impact, sCD163 impact, and other findings shown for reports 
on monocyte/macrophage activation during ART.  
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noted in patients with CD4 counts below 350 cells/mm3, but this study did not 
examine other markers of T-cell or monocyte/macrophage activation (34). 
Plasma sCD163 was reduced to normal levels in patients treated during early 
infection, but not those treated at later stages (177). Additionally, cross-sectional 
studies suggest sCD163 does not reach normal levels with viremic suppression 
(150, 176, 177, 179). Plasma sCD14 is even less plastic. Longitudinal studies 
have found elevated sCD14 levels persist despite viral suppression (86, 174, 
177) and are only partially resolved after extended ART (174, 175). Cross-
sectional comparisons have demonstrated that sCD14 levels are not resolved to 
normal levels in ART-treated patients (91, 152, 174, 178, 179). 
 
 A major component of monocyte/macrophage activation during viremia is 
the upregulation of ISG expression (Reviewed in Section 1.4). Among these, 
CD169 (Sialoadhesin, SN, SIGLEC1) is a surface-expressed ISG (IFN-α, IFN-γ 
inducible) on monocytes, macrophages, and dendritic cells that is highly 
expressed during HIV-1 infection (143, 154, 156) and other inflammatory 
diseases (155, 157). CD169 can also facilitate trans-infection of target cells by 
both monocytes and dendritic cells (156, 158, 159). Its expression can be 
reversed with viral suppression after ART in SIV infection (160). 
 
 Studies have suggested that CCR5 antagonism may improve resolution of 
T-cell activation during ART initiation (temporary advantage) (214, 215) yet data 
is not uniform across intensification studies to date (215-218). Regarding 
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monocyte/macrophage activation, Maraviroc-inclusive ART has yielded mixed 
results regarding sCD14 resolution (216, 217, 219, 220) (Table 3.2). Some  
 
Table 3.2: Monocyte/macrophage activation during non-standard ART. 
Study type, sCD14 impact, sCD163 impact, and other findings shown for reports 
on monocyte/macrophage activation during non-standard ART (Maraviroc, 
Elvitegravir, Rosuvastatin). 
 
variability may be attributed to cohort and therapy differences, as intensification 
studies often target immunological non-responders (215, 217, 218). Taken 
together, the immunological impact of a Maraviroc-inclusive regimen in patients 
initiating ART from advanced infection has not been described. Although addition 
of CCR5 antagonism (Maraviroc) did not impact the degree of CD4 recovery in 
patients starting with nadir CD4 counts in the parent study (221), we hypothesize 
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it may reduce monocyte/macrophage activation by inhibiting 
monocyte/macrophage recruitment and viral-CCR5 interactions (222, 223). 
 
 In this chapter, we describe the changes in biomarkers of monocyte and 
macrophage activation and the impact of CCR5 antagonism in patients initiating 
ART in advanced disease (CD4 count below 100 cells/mm3). Our primary 
analysis aimed at determining the degree and kinetics of reversal of 
monocyte/macrophage activation with respect to T-cell activation, while 
secondary analysis addressed the impact of CCR5 antagonism on 
monocyte/macrophage activation. With 24 weeks of suppressive ART, we 
observed a differential reversal of biomarkers of monocyte/macrophage 
activation. Apart from increases in the percentage of peripheral blood monocytes 
expressing CCR5, no Maraviroc-mediated effects on monocyte/macrophage 
activation markers with ART were noted. 
 
3.2 Antiretroviral therapy in HIV-1 infected individuals with CD4 count 
below 100 cells/mm3 results in differential reversal of 
monocyte/macrophage activation 
 
3.2.1 Study cohort and baseline characteristics 
 Patients were recruited in the CADIRIS (CCR5 antagonism to decrease 
the incidence of immune reconstitution inflammatory syndrome) study examining 
the impact of Maraviroc-inclusive ART on IRIS incidence in low CD4 count HIV-1 
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patients initiating ART between five study sites in Mexico and one in South Africa 
(221). Patients received placebo or Maraviroc (600 mg) in addition to a 
background of Efavirenz (EFV, 600 mg), Tenofovir, (TDF, 300 mg), and 
Emtricitabine, (FTC, 200 mg), and plasma and PBMC were isolated from whole 
blood at 0 (pre-ART), 12, and 24 weeks. Archived plasma and PBMC were 
analyzed from 65 patients from the South Africa site that were virologically 
suppressed at week 24 (defined as viral load less than 400 HIV-1 RNA 
copies/mL). Inclusion criteria of the parent study required a baseline CD4 count 
of less than or equal to 100 CD4 T-cells/mm3, allowing us to investigate the 
impact of ART-mediated suppression on monocyte/macrophage activation 
biomarkers in advanced HIV-1 infection. Consistent with the parent study, no 
difference in gender, age, and baseline clinical metrics (viral load, CD4 count, 
CD8 count) was observed between the placebo and Maraviroc groups in the sub-
study (Table 4.3). Baseline T-cell and monocyte/macrophage activation markers 
were also not different between groups. 
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Table 3.3: Cohort baseline characteristics. 
Demographic, clinical, and T-cell and monocyte/macrophage activation baseline 
metrics are shown for ART + Placebo group, ART + Maraviroc group, and total 
ART cohort. P values were calculated by Mann-Whitney test for all comparisons, 
excluding gender which was calculated by Fisher’s exact test.  
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3.2.2 Change in T-cell count and biomarkers of T-cell activation 
 Median CD4 count increased from 46 and 41 (placebo and Maraviroc 
group) to 149 and 177 cells/mm3 during 24 weeks ART (P < 0.0001 for both 
groups, P = 0.5710 between groups at week 24) (Figure 3.1A). The parent study 
and others have observed higher CD8 counts in Maraviroc groups during ART 
(217, 221), and the sub-study observed a similar trend (P = 0.0579, week 24) 
(Figure 3.1B). As these patients initiated therapy from advanced infection, we did  
 
Figure 3.1: CD4 and CD8 T-cell count during ART. 
Shown are placebo (blue) versus Maraviroc (red) group CD4 count (A) and CD8 
count (B) absolute and relative to baseline change. Median and interquartile 
range (IQR) are displayed, and only patients with all time points are shown. 
Mann Whitney comparison between groups was performed at each time point 
with P < 0.05 considered significant and displayed. Longitudinally, Friedman test 
and post hoc Dunn test were performed with P < 0.05 considered significant and 
displayed. 
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not expect uniform decreases in T-cell activation markers by week 24 (24, 25). 
However, T-cell activation, measured by CD38+, HLA-DR+ T-cells, was uniformly 
reduced in both CD4 and CD8 T-cells in both groups by week 24 (P < 0.0001 for 
CD4 and CD8) (Figure 3.2, 3.3A, B). At week 24, we detected a small but 
significant difference in CD38+, HLA-DR+ CD4 T-cells (3.555% in placebo versus 
2.620% in Maraviroc, P = 0.0072, Figure 3.3A). The percent of CD4 and CD8 T-
cells expressing CD38 was also significantly reduced in both arms (P < 0.001 for 
CD4 and CD8) (Figure 3.3C, D). Independent of group, the percent of CD4 or 
CD8 T-cells expressing CD38 or CD38 and HLA-DR was reduced by 49-70% 
from baseline (Figure 3.3). 
 
Figure 3.2: Representative T-cell activation biomarkers during ART. 
Representative donor CD4 (top) and CD8 (bottom) T-cell expression of CD38 (x-
axis) and HLA-DR (y-axis) during ART are shown. 
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Figure 3.3: T-cell activation markers during ART. 
Shown are placebo (blue) versus Maraviroc (red) group percent of CD38+, HLA-
DR+ CD4 T-cells (A), CD38+, HLA-DR+ CD8 T-cells (B), CD38+ CD4 T-cells (C), 
and CD38+ CD8 T-cells (D) during ART absolute and relative to baseline change. 
Median and interquartile range (IQR) are displayed, and only patients with all 
time points are shown. Mann Whitney comparison between groups was 
performed at each time point with P < 0.05 considered significant and displayed. 
Longitudinally, Friedman test and post hoc Dunn test were performed with P < 
0.05 considered significant and displayed. 
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 3.2.3 In vivo impact of Maraviroc on monocyte/macrophage activation 
markers and T-cell and monocyte CCR5 expression  
 Markers of monocyte/macrophage activation were not significantly 
different between groups (data not shown). We observed a higher percentage of 
CCR5 expressing CD4 T-cells, CD8 T-cells, and monocytes in PBMC of the 
Maraviroc group during ART (Figure 3.4), as evidence of therapy exposure and 
as reported by others (217). We interpret this to reflect a lack of ligand-mediated 
receptor internalization and/or lack of tissue migration of CCR5+ cells in the 
Maraviroc group. As we did not detect an impact of Maraviroc on 
monocyte/macrophage biomarkers of activation, from this point onwards, we 
opted to analyze ART-mediated changes independent of study group. 
 
Figure 3.4: Maraviroc-inclusive ART results in a greater percent of CCR5-
positive T-cells and monocytes in PBMC. 
Shown are percent of CCR5-positive CD4 T-cells (A), CD8 T-cells (B), and total 
monocytes (C) during ART in placebo (Pla) versus Maraviroc (Mvc) groups. 
Mann Whitney comparison between groups was performed at each time point 
with P < 0.05 considered significant and displayed. 
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3.2.4 ART reduces cell-associated and soluble markers of 
monocyte/macrophage activation 
 The reversal of cell-associated and soluble markers of 
monocyte/macrophage activation is not well-described during ART in advanced 
infection, and their potential reversal may inform prognosis of such cohorts, as 
markers of monocyte/macrophage activation are associated with 
pathogenesis/predict outcome (78, 80, 91, 92, 176, 180). Based on previous ART 
studies (Reviewed in Section 1.5, Table 3.1), we predicted ART and viral 
suppression will reduce the percent of the CD14++CD16+ intermediate 
monocytes, the percent of CD163+ monocytes, and the level of plasma sCD163, 
while plasma sCD14 will not change. Within total monocytes, the percent of 
CD14++CD16+ intermediate monocytes (Figure 3.5) and CD163+ monocytes were  
 
 
Figure 3.5: Representative change in monocyte subsets during ART. 
Representative donor monocyte subsets during ART determined by CD14 (x-
axis) and CD16 (y-axis). Subsets are defined as classical (CD14++CD16-), 
intermediate (CD14++CD16+), and non-classical (CD14+CD16++) subsets.  
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Figure 3.6: Monocyte/macrophage activation biomarkers during ART. 
Shown are percent of intermediate monocytes (A), CD163-positive monocytes 
(B), plasma sCD163 (C), and plasma sCD14 (D) absolute and relative to 
baseline change. Longitudinal comparisons display median and interquartile 
range with Tukey’s method using the Friedman test and Dunn post hoc test with 
P < 0.05 considered significant and displayed. 
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significantly reduced by week 24 (P < 0.0001 and P = 0.0004) with a relative 
reduction of 61.96% and 55.54% from baseline (Figure 3.6A, B, Table 3.4). 
Complete subset and subset activation markers are provided in Table 3.5. In 
plasma, sCD163 was also significantly reduced at week 24 with a relative 
reduction of 28.04% from baseline (P < 0.0001) (Figure 3.6C). Plasma sCD14 
was significantly reduced by week 24 but with only a 14.70% reduction from 
baseline (P = 0.0081) (Figure 3.6D). We show a reduction in both cell-associated 
and soluble markers of monocyte/macrophage activation. 
 
 
Table 3.4: Total monocyte activation markers. 
Median and interquartile range are displayed. Values for week 12 and 24 are 
displayed in red if decreased (P < 0.05) from Week 0. Friedman test and Dunn 
post hoc test. 
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Table 3.5: Monocyte subsets and subset activation markers. 
Median and interquartile range are displayed. Values for week 12 and 24 are 
displayed in red if decreased (P < 0.05) from Week 0. Friedman test and Dunn 
post hoc test. 
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3.2.5 Reduction of markers of monocyte ISG expression 
 We also investigated the reversal of markers of ISG expression (CD169, 
tetherin) as ISG expression in monocytes/macrophages may contribute to HIV-1 
associated immune dysfunction (Reviewed in Section 1.4). CD169 was highly 
expressed on total monocytes pre-ART and was reduced to marginal expression 
after 12 weeks ART (P < 0.0001) (Figure 3.7A, Table 3.4). Tetherin expression 
was also reduced by 24 weeks (P = 0.0153, 38.94% reduction) (Figure 3.7B, 
Table 3.4). Both CD169 and tetherin expression were significantly reduced in all 
monocyte subsets at weeks 12 and 24 (Table 3.5). The rapid and near complete 
reduction of monocyte CD169 expression stands out as a very early and 
reversible marker of HIV-1 viremia, suggesting that control of viral replication 
removes a major stimulus for monocyte ISG induction. 
 
 Figure 3.7: ART reduction of monocyte ISG markers. 
Shown are the percent of CD169+ monocytes (A) and tetherin expression (B) 
with representative donors (left), absolute values (middle), and change relative to 
baseline (right) during 24 weeks ART. Longitudinal comparisons display median 
and interquartile range with Tukey’s method using the Friedman test and Dunn 
post hoc test with P < 0.05 considered significant and displayed.  
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3.2.6 Correlates of monocyte apoptosis resistance during ART 
Previous findings have demonstrated that signaling through CCR5 (103, 
105) and elevated intracellular monocyte zinc content (104) are mechanisms 
associated with apoptosis resistance in monocytes from viremic HIV-1 patients. 
To address the potential reversal of these mechanisms, we investigated 
monocyte CCR5 expression and zinc content (Figure 3.8). As noted earlier, the 
percent of monocytes expressing CCR5 was higher in the Maraviroc group 
during therapy (Figure 3.8B); however, no difference in zinc content was noted  
 
Figure 3.8: Correlates of monocyte apoptosis resistance during ART. 
Representative (Maraviroc patient) (A) and cohort (B) CCR5 expression during 
24 weeks ART in placebo (Pla) and Maraviroc (Mvc) groups. Group comparisons 
display median and interquartile range using the Mann Whitney test. Monocyte 
zinc content (representative (C), relative value (D), relative change (E)) during 24 
weeks ART. The dotted line (D, E) represents the MFI of the HIV (-) standard 
repeated during each experiment. Longitudinal comparisons display median and 
interquartile range using the Friedman test and Dunn post hoc test with P < 0.05 
considered significant and displayed.  
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between therapy groups (data not shown). Zinc content was decreased by 12 
weeks in total monocytes (Figure 3.8D) and the classical subset, but was 
unchanged in the intermediate and non-classical subset (Table 3.5). We interpret 
ART may reduce the anti-apoptotic impact of monocyte zinc content, by 
reduction within classical monocytes or reduction of the size of the intermediate 
subset. 
 
3.2.7 Correlates in the change of T-cell and monocyte/macrophage 
activation biomarkers 
We last examined the association of change within the activation markers 
examined and CD4 count to determine which monocyte/macrophage markers 
would inform the resolution of T-cell activation and CD4 reconstitution (Figure 
3.9, total monocytes; Figure 3.10, monocyte subsets). Interestingly, the change 
 
Figure 3.9: Correlation of change in T-cell and total monocyte/macrophage 
activation biomarkers. 
Spearman rho is displayed with P < 0.05 considered significant and displayed in 
green, P < 0.01 in blue, and P < 0.001 in red. Median 24 week change is shown 
in column one parentheses. 
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in CD4 count was negatively associated with the change in CD163+ total 
monocytes, suggesting the reversal of CD163 expression may be useful as a 
monocyte benchmark of immune reconstitution. Data show that the change in 
CD8 activation (CD38+, HLA-DR+) was associated with change in CD169 and 
tetherin expression on total monocytes. Interestingly, CD4 or CD8 T-cell 
activation (CD38+, HLA-DR+) change was not associated with changes in the 
CD14++CD16+ intermediate subset, CD163 expression, or plasma sCD14. These 
data suggest decreases in markers of T-cell activation, observed after viremic 
suppression, are mirrored by monocyte markers of ISG expression (CD169, 
tetherin) as opposed to those associated with inflammatory cascades. 
 
Figure 3.10: Correlation of change in T-cell and monocyte 
subset/macrophage activation biomarkers. 
Spearman rho is displayed with P < 0.05 considered significant and displayed in 
green, P < 0.01 in blue, and P < 0.001 in red. Median 24 week change is shown 
in column one parentheses.  
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3.3 Discussion, limitations, and future directions 
Our data indicate that ART-mediated viral suppression in advanced HIV-1 
infection results in differential reduction of monocyte/macrophage activation 
markers relative to T-cell activation markers. Additionally, CCR5 antagonism 
(Maraviroc) did not impact markers of monocyte and macrophage activation 
beyond use of ART alone. The latter indicates suppression of viral replication is 
dominant over CCR5 antagonism in determining change in innate immune 
activation. However, as we did not examine activation in tissue, as done by other 
studies (217), we cannot exclude a long-term impact of CCR5 antagonism on 
tissue damage, repair, and reconstitution, as should be a focus of future studies. 
Although other studies have addressed retention of activation in monocyte 
subsets after viral suppression, our study reports for the first time the differential 
changes observed when ART is initiated in advanced infection. 
 
 While we generally observed decreases across biomarkers of monocyte 
and macrophage activation with viral suppression, different degrees of change 
were observed between markers. At one end, monocyte CD169 expression was 
greatly reduced by 12 weeks (median 97.94% relative reduction), representing 
the marker with the closest alignment to control of viral replication. Others have 
described a correlation of CD169 expression and viral load (156); however, we 
did not detect this association, possibly due to the narrow viral load distribution of 
our cohort (Log viral load (copies/mL): 4.378–6.383). CD169 expression is 
reversed with ART in the SIV macaque model (160). Our data support this finding 
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in HIV-1 patients initiating ART during advanced infection. The level of 
CD14++CD16+ (intermediate) monocytes was significantly reduced by greater 
than 50% by week 24 (Figure 3.6), aligning with similar ART-mediated decreases 
(34, 35). 
 
 Unexpectedly, CD163 monocyte expression was not correlated with 
sCD163. As follows, monocyte CD163 expression may represent independent 
immunological pressures from those driving receptor shedding. Interestingly, our 
measurement of CD163 expression may under-represent in vivo expression 
levels as others have described lower values on PBMC as compared to whole 
blood staining (CD163 antibody clone GHI/61 used both here and referenced 
studies) (31, 224). Our prior work has described the impact of viremia on 
monocyte ISG expression and apoptotic regulation (103-105, 225). Our data 
support the relationship between viral suppression and an immediate reduction in 
ISG expression in contrast to the change in markers of TLR-mediated activation. 
Plasma sCD14 was the least plastic biomarker over 24 weeks ART, supporting 
previous studies (86, 174, 175, 177, 179). Our data suggest sCD14 is stable in 
the majority of patients during ART treatment in advanced HIV-1 infection. 
 
 The absence of age, gender, and geographically-matched HIV-
seronegative donors limits our ability to interpret resolution to normal levels. 
However, this does not affect our ability to interpret what variables best reflect 
changes in T-cell activation, viral suppression, and immune reconstitution. 
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Second, the absence of functional responses limits assessment regarding 
retention of plasma sCD14 and altered TLR responses. Third, data analysis on 
patients with viral suppression by week 24 and complete datasets (week 0, 12, 
24) may introduce selection bias limiting our interpretation to patients with 
favorable clinical outcomes. Finally, due to the use of cryopreserved PBMC and 
the absence of gene expression data, we are unable to directly measure 
monocyte apoptosis and are therefore limited to describing changes in variables 
that are expect to reflect apoptosis resistance mechanisms (Figure 3.8) (103-
105). 
 
 In summary, we describe a spectrum of reduction of indicators of 
monocyte/macrophage activation in advanced HIV-1 infection during 24 weeks 
ART. We also differentiate activation variables closely associated with control of 
viral replication (CD169), CD4 reconstitution (CD163), and those showing a 
strong relationship with decreased CD8 T-cell activation (CD169 and tetherin). 
The lack of greater change in both sCD14 and sCD163 after ART suggests that 
microbial translocation and associated activation may be of greater concern in 
advanced infection despite viral suppression. 
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3.4 Materials 
 
3.4.1 Donor population 
 HIV-1 seropositive patients (n = 65; 56.9% female; median age = 38 
years) were recruited as part of sub-study B (South Africa study site) within the 
CADIRIS parent study (221). Inclusion criteria targeted ART-naïve individuals 
with a CD4 count less than 100 cells/mm3 (Table 3.3). Patient data with failure to 
suppress viral load below 400 RNA copies/mL by week 24 were excluded from 
analysis. Patients received placebo or Maraviroc (600 mg) in addition to a 
background of Efavirenz (EFV, 600 mg), Tenofovir, (TDF, 300 mg), and 
Emtricitabine, (FTC, 200 mg), and plasma and PBMC were isolated from whole 
blood at 0 (pre-ART), 12, and 24 weeks. Data showing less than the total cohort 
reflect unavailable patient material or limited assay capacity. Figures expressing 
paired, longitudinal data (Figure 3.1, 3.3, 3.6, 3.7, 3.8) include patients with only 
complete data (0, 12, and 24 weeks). All participants produced informed consent 
in accordance with clinical trial NCT 00988780. 
 
3.4.2 T-cell and monocyte flow cytometry 
 T-cell activation and monocyte activation were characterized by flow 
cytometry analysis of PBMC samples (Table 3.6). T-cell activation markers were 
measured in PBMC were thawed and stained with CD3-V450, CD38-APC, HLA-
DR-APCH7, CD4-PerCPCy5.5, CCR5-PE, and CD8-FITC. Monocyte activation 
and ISG expression markers were measured in PBMC with CD3-V450  
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Table 3.6: PBMC Flow cytometry panel.  
  
(exclusion), CD14-APC, CD16-APCH7, CCR5-PerCPCy5.5, CD169-PE, and 
CD163-FITC as well as CD14-V450, CD16-APCH7, CD3-PerCPCy5.5 
(exclusion), CD317-PE (Tetherin), and CCR5-FITC. Cell type-matched gates 
(CD3+ for T-cells, CD14, CD16 combined gate for monocytes) isotypes were 
used for negative/positive gating. Aqua Live/Dead (Life Technologies) was used 
for dead cell exclusion. All flow cytometry antibodies were purchased from BD 
Biosciences (with the exception of CD169-PE from eBioscience and CD317-PE 
from BioLegend) and used per the manufacturers’ instructions. T-cells were 
gated on singlets using forward scatter height and area, lymphoid scatter profile, 
CD3+ cells, followed by CD4+ and CD8+ T-cells (Figure 3.11A). Monocytes were 
gated on singlets, monocyte scatter profile, CD3 exclusion, total monocytes 
(CD14, CD16 combined gate), and the monocyte subsets, classical monocytes 
(CD14++CD16-), intermediate monocytes (CD14++CD16+), and non-classical 
monocytes (CD14+CD16++) (Figure 3.11B, C). All figures depicting monocyte 
activation markers represent the total monocyte population. Flow cytometry data  
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Figure 3.11: Flow cytometry gating. 
Representative T-cell (A) and monocyte (B) flow cytometry gating strategy. 
Target molecule expression was evaluated on CD4 and CD8 subsets for T-cells 
(A) and total monocytes and classic, intermediate, and non-classical subsets for 
monocytes (B-C).  
 
analysis and images was generated with FlowJo software (TreeStar). All flow 
cytometry data reported display percent of positive cells relative to the parent 
population with the exception of tetherin (MFI) (Figure 3.7B) and zinc content 
(Figure 3.8C-E). 
 
3.4.3 Monocyte zinc content 
 Monocyte zinc content was determined in PBMC using CD11b-V450, 
CD14-APC, CD16-APCH7, CD3-PerCPCy5.5 (exclusion), and 5 μM Newport 
Green DCF Diacetate cell permeate zinc indicator (Life Technologies). Control 
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PBMC from the same HIV-seronegative donor was thawed each time the assay 
was performed and stained in parallel as a standard to which each sample was 
normalized. The MFI (mean fluorescence intensity) of each sample was divided 
by the MFI of the control donor in order to calculate the relative zinc content 
(Figure 3.8C). 
 
3.4.4 Plasma activation markers 
 Plasma samples were assayed by ELISA for sCD14 (R&D Systems) and 
sCD163 (Trillium Diagnostics), using 1:500 dilutions, according to the 
manufacturers’ instructions. Plates were read on a BioTek Synergy HT 
microplate reader at 450 nm with the appropriate wavelength corrections. 
 
3.4.5 Statistical analysis 
 All dot and box-and-whisker plots were generated and statistically tested 
using Prism 6 (GraphPad, La Jolla, CA) and two-group longitudinal graphs 
(Figure 3.1, 3.3) were generated using Microsoft Excel. All graphical plots show 
median and interquartile range and box-and-whisker plots are displayed using 
Tukey’s method. Relative change was calculated as percent change relative to 
week 0 (Pre-ART). Group comparisons at the same time point were performed 
using the Mann-Whitney test (two-tailed). Longitudinal comparisons were 
performed using the Friedman test with the Dunn post hoc test between time 
points. P values less than 0.05 were considered significant and are displayed. 
Correlation of T-cell and monocyte/macrophage biomarker change (Week 24-
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Week 0) (Figure 3.9, 3.10) was calculated with Spearman’s test (two-tailed) with 
rho displayed and P < 0.05 in green, P < 0.01 in blue, and P < 0.001 in red. 
Correlation matrices (Figure 3.9, 3.10) were not adjusted for multiple testing. 
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CHAPTER 4: Mechanistic investigation of HIV-1 induced 
monocyte apoptosis resistance: Impact of ISG12 family 
gene expression 
 
4.1 Introduction 
 4.1.1 Background 
 4.1.2 Rationale 
4.2 IFI6 and IFI27 ectopic expression system and induction in vitro 
4.3 Impact of IFI27 over-expression on apoptosis in Monomac1 cell line 
4.4 Discussion, limitations, and future directions 
4.5 Materials 
 4.5.1 Generation of inducible expression Monomac1 cell lines 
 4.5.2 Apoptosis induction in transduced Monomac1 cell lines 
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4.1 Introduction 
 
4.1.1 Background 
 Pilot RNA sequencing and RT-PCR follow-up highlighted members of the 
ISG12 gene family as candidate genes that may contribute to the regulation of 
monocyte apoptosis during HIV-1 infection (Reviewed in (189, 190)). Within this 
family, expression of IFI6, IFI27, and IFITM2 was elevated in HIV (+) individuals 
(compared to HIV (-) individuals) and associated with viral load (Table 2.4, Figure 
2.13). 
 
 The ISG12/FAM14 family consists of low molecular weight hydrophobic 
(often membrane-associated) proteins highly induced by interferons and during 
viral infection (189, 190, 193, 195, 226, 227). IFI6/G1P3 is a 13 kDa protein with 
known anti-apoptotic properties (190). Specifically, IFI6 is upregulated in 
myeloma and gastric cancer cell lines and facilitates apoptosis resistance to 
intrinsic, mitochondrial-mediated apoptosis (191, 192). Upregulation of IFI6 
during Dengue virus infection of endothelial cells is associated with protection 
from infection-induced apoptosis (228). 
 
 IFI27 is a 12 kDa hydrophobic protein (encoded by ISG12a/FAM14D) that 
localizes to the mitochondrial membrane and facilities mitochondrial-mediated 
pro-apoptotic impact (190, 193), similar to mouse ISG12b2 (195). IFI27 
expression is upregulated during various viral infections (VSV, CMV, HCV, RSV, 
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HIV) (140, 193, 195, 226, 227), and may predict treatment outcome during HCV 
infection (229, 230). Similar to IFI27, IFITM2 has also be described as a pro-
apoptotic ISG12 member (194). Also members of the ISG12/FAM14 family, the 
IFITM proteins (IFITM1-3) and the ubiquitin-like ISG15 protein have 
demonstrated anti-viral and anti-HIV properties, but are beyond the focus of 
these studies (170, 196, 231-233). 
 
4.1.2 Rationale 
 An increase in monocyte apoptosis with increasing viral load paired was 
paired with elevated ISG expression (Chapter 2). The latter prompted an 
investigation of underlying mechanistic pathways that may account for this effect. 
This chapter will investigate the independent role of ISG12 family gene 
expression on monocyte apoptosis sensitivity. Based on the observation that 
ISG12 family expression was elevated in HIV (+) patients with elevated monocyte 
apoptosis ex vivo (Chapter 2), we tested the hypothesis that elevated pro-
apoptotic ISG12 family gene expression would be sufficient to increase apoptosis 
sensitivity in a monocytic cell line. Specifically, we tested if induced expression of 
IFI6 or IFI27 could modulate monocyte apoptosis outcomes. Work described in 
this chapter includes the design and implementation of an inducible gene 
expression system to gauge the impact of pro- and anti-apoptotic ISG12 
members on monocyte apoptosis. 
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4.2 IFI6 and IFI27 ectopic expression system and induction in vitro 
 We tested the hypothesis that ectopic expression of IFI6 or IFI27 would 
impact apoptosis outcome in a monocytic cell line. Based on the described 
apoptotic functions of these proteins (Section 4.1), our hypothesis predicts 
expression of IFI6 would protect cells from apoptosis and expression of IFI27 
would sensitize cells to apoptosis. 
 
 To investigate our hypothesis, we generated stably transduced cell lines 
expressing each of the genes of interest under an inducible promoter. Three 
splice variants of IFI6 have been described (189): the 130 amino acid IFI6a, 
IFI6b with four additional amino acids at position 24, and IFI6 with 8 additional 
amino acids at position 24; however, to our knowledge, no functional impact of 
these variants has been described. IFI6a (130aa) was chosen based on template 
availability. IFI27/ISG12 exists in four isoforms, the full length ISG12, a splice 
variant lacking exon 2 designated ISG12-S, a three amino acid deleted variant 
designated ISG12Δ, and the combined ISG12-SΔ (189, 234). We chose the full 
length ISG12 based on template availability and because it retains both 
transmembrane domains (189). 
 
 The Monomac1 (MM1) cell line, established from an acute monocytic 
leukemia, was chosen for its ease of culture for flow cytometry applications, 
functional capacity (produces TNF-α after LPS stimulation, data not shown), and 
permissiveness to HIV-1 infection (235, 236). Cloning primers were engineered 
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with 5’ BamHI and 3’ Nhe1 restriction sites and IFI6 and IFI27 gene fragments 
were generated from commercial templates (Figure 4.1). A dual-transduction  
 
Figure 4.1: IFI6 and IFI27 cloning primers. 
Shown are BamHI (red) and NheI (green) restriction site-engineered primers for 
the cloning of IFI6 and IFI27 gene fragments into delivery plasmid.  
 
system was set up using the pLU-EF1aL-rtTA3-iCherry (“helper plasmid”) and 
pLU-TREmin-MCS-pGFP (“transducing plasmid”) constructs in a VSV-delivery 
system (Figure 4.2). The mCherry (under the IRES promoter) and eGFP (under 
the hPGK promoter) provide fluorescent markers to sort and purify dual-
transduced cells. The gene of interest is cloned into the transducing plasmid 
downstream of the Tet-response element (TREmin) and requires both rtTA3, 
constitutively produced from the helper plasmid, and exogenous Doxycycline 
treatment to induce gene expression. Three transducing plasmids/viruses were 
generated: TREmin-MCS-pGFP (no gene of interest control), TREmin-IFI6-
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pGFP, and TREmin-IFI27-pGFP, each to be co-transduced with the mCherry 
helper virus. 
 
Figure 4.2: Gene delivery plasmids. 
Shown are plasmid maps for “helper plasmid” (red) and “transducing plasmid” 
(green). rtTA3 gene product from “helper plasmid” and exogenous doxycyline 
treatment are both required for gene expression from inducible promoter on 
“transducing plasmid.”  
 
 We titrated the 3-day transduction capacity of each virus and found 
greater than 90% transduction at 2.5 μL of each eGFP virus (MCS, IFI6, IFI27). 
The mCherry helper virus had less separation and up to 23.7% transduction at 5 
μL of virus (Figure 4.3A-B) (Virus treatment given at μL virus stock per 2 million 
cells). We then examined the co-transduction efficiency of these viruses and 
found 38.8-44.5% co-transduction (2.5 μL each GFP virus plus 5 μL rtTA3-
mCherry) (Figure 3.3C). We proceeded to sort two single transduced populations 
(MCS-GFP alone and rtTA3-mCherry alone) as controls (i.e. compensation) and  
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Figure 4.3: Single and co-transduction titrations. 
(A-B) Single transduction titration (0-5 μL transducing virus) of control (MCS-
GFP), IFI6-GFP, IFI27-GFP, and rtTA3 transducing viruses. (C) Dual-
transduction of rtTA3-mCherry (2.5 μL) and MCS-GFP (left), IFI6-GFP (center), 
and IFI27-GFP (right). Plots show mCherry (x-axis) and GFP (y-axis) 
fluorescence.  
 
the three target co-transduced lines (Figure 4.4A-B). Although the co-
transduction efficiency was much lower (5-7%) compared to the previous titration 
(38-44%), we successfully purified all target cell lines. Sorted cells were 
expanded by subsequent culture and archived as stock cultures. Cultures were 
periodically restarted from stored stocks as we also noted that time in culture 
resulted in eventual dilution of the transduced population (Figure 4.4C). This may 
be the result of loss of reporter expression or outgrowth of a small population of 
un-transduced contaminants. 
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Figure 4.4: Dual-transduction and sorting. 
(A) Single and dual-transduced cell line set up showing viruses used and cells 
transduced/sorted. (B) Transduction efficiency and populations sorted. Dual 
transduction (4, 5, 6) show GFP (x-axis) and mCherry (y-axis) fluorescence. (C) 
Transduced stocks were periodically examined for reporter expression. Graph 
shows the remained single or dual-transduced (by indicator) cells in active 
culture.  
 
 We then tested for an apoptosis response in the Monomac1 cell line by 
titrating apoptosis-inducing agents (independent of target gene induction). 
Cadmium chloride (CdCl2), used as an oxidative stress inducer in primary 
monocytes (103-105, 225), was titrated on the cell line. A target of 15% caspase-
positive cells at 35 μM CdCl2 was chosen (Figure 4.5A) (n=3). The 
topoisomerase II inhibitor, etoposide (237), was also evaluated and induced 
apoptosis on this cell line (Figure 4.5B). 
103 
 
 
Figure 4.5: Monomac1 apoptosis induction titration. 
(A) Dose-response titration of CdCl2 treatment (μM) versus apoptosis induction 
(measured by active caspase-3) (representative of n=3 replicates). (B) Dose-
response titration of etoposide treatment (μg/mL) versus apoptosis induction 
(measured by active caspase-3) (representative of n=2 replicates).  
 
4.3 Impact ofIFI6 and IFI27 over-expression on apoptosis in Monomac1 cell 
line 
 We first confirmed specific gene induction by RT-PCR using a 24 hour, 0-
1000 ng/mL doxycycline dose-response (Figure 4.6). Doxycycline did not induce 
expression of off-target genes in any cell line, such as the Rb1 or the prototypic 
ISG, Mx1, in any cell line (Figure 4.6A-B). IFI6 RNA expression peaked at 4.5 
expression units in the IFI6 cell line (Figure 4.6C), comparable to HIV (+) RNA  
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Figure 4.6: Monomac1 gene induction dose response. 
Shown is Rb1 (A), Mx1 (B), IFI6 (C), and IFI27 (D) gene expression measured by 
RT-PCR in transduced cell-lines treated with 0-1000 ng/mL doxycycline for 24 
hours. Show are untransduced MM1 (blue), MCS-no gene control (red), IFI6-
transduced (green), and IFI27-transduced (purple) cell lines.  
 
expression ex vivo (Table 2.4, Figure 2.13). IFI27 was robustly induced in its 
specific cell line (Figure 4.6D), above 6000 units at 1000 ng/mL doxycycline, 
again, comparable to ex vivo HIV (+) patient monocytes (Table 2.4, Figure 2.13) 
and IFN-α treated HIV (-) monocytes in vitro (Figure 2.5). These data 
demonstrate induction of specific genes of interest in the target cell lines. Based 
on the ISG12 induction kinetics observed with IFN-α treatment (Figure 2.6) we 
also conducted a time course of gene expression in our inducible cell lines (at 
1000 ng/mL doxycycline) (Figure 4.7). Similar to IFN-α treatment in primary 
monocytes, IFI6 expression peaked at 4 hours post induction in the inducible 
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system and declined thereafter (Figure 4.7A). IFI27 expression exceeded 1000 
expression units by 8 hours and remained elevated beyond 24 hours (Figure 
4.7B). Based on induction optimization experiments, functional experiments were 
carried out with 1 ng/mL doxycycline and 4-8 hours of post-induction gene 
expression. 
 
Figure 4.7: Monomac1 gene induction time course. 
IFI6 (A) and IFI27 (B) cell lines were treated with 1000 ng/mL doxycycline and 
RNA was isolated over time. Show is gene expression of the target gene 
measured by RT-PCR.  
 
 We tested the impact of IFI27 expression on Monomac1 apoptosis 
outcome (constitutive and etoposide-induced) (Figure 4.8). IFI27 and MCS cell 
lines were treated with doxycycline (1000 ng/mL, 8 hours), inducing expression in 
the IFI27 line (data not shown), followed by etoposide apoptosis challenge (18 
hour, 0, 1, and 5 μg/mL) (Figure 4.8A-B). Data show similar constitutive and 
etoposide-challenged apoptosis response in the presence (IFI27-Doxy) or 
absence (MCS-Doxy) of IFI27 expression (Figure 4.8A-B) and in un-induced 
conditions (IFI27-None) (Figure 4.8B). We also monitored apoptosis in the IFI27 
cell line (relative to untransduced Monomac1) over a 14 hour gene induction  
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Figure 4.8: IFI27 transgene expression and apoptosis outcome in 
Monomac1 cells. 
(A) Shown are apoptosis plots (active caspase-3 versus 7-AAD) of the MCS-
control (top row) and IFI27 (bottom row) cell lines treated with 1000 ng/mL 
doxycycline for 8 hours, washed, and challenged overnight (18 hr) with 0, 1, or 5 
μg/mL etoposide. (B) Quantification of induction-challenge experiment in (A) with 
doxy-induced MCS (green), doxy-induced IFI27 (purple), un-induced-MCS (blue), 
and un-induced IFI27 (red). (C) Time-course of untransduced and IFI27 cell line. 
Gene-expression was induced in all conditions (1000 ng/mL doxycycline) and 
cells were untreated or etoposide-challenge (6 μg/mL) at 9 hours.  
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(1000 ng/mL doxycycline) with etoposide apoptotic challenge (6 μg/mL) 
beginning at 9 hours and, again, did not detect augmentation of apoptosis in the 
presence of IFI27 gene expression (Figure 4.8C). 
 
 Based on the described function of IFI27, we sought to determine if IFI27 
expression had any upstream effect on mitochondrial membrane potential (195). 
IFI27 and MCS cell lines were treated with doxycycline (250 ng/mL, 4 hours). 
Cells were challenged with etoposide (600 ng/mL) and mitochondrial membrane 
potential (MitoProbe DilC1) and apoptosis (Annexin V) were monitored for 24 
hours (Figure 4.9). Disruption of membrane potential, measured as the percent of 
MitoTracker-negative cells of the transduced population (mCherry+, GFP+), was 
observed in both MCS and IFI27 cell lines at 24 hours at 41.7% and 41.1% 
(etoposide challenged) and 9.7%, 9.3% (no challenge), respectively. No 
differences were detected at any time point (n=3 internal replicates). These data 
show expression of the IFI27 transgene did not have a detectable impact on 
mitochondrial membrane potential or augment apoptosis outcome in the 
Monomac1 cell line. 
 
 Multiple IFI6 expression-apoptosis experiments were conducted in parallel 
(CdCl2/etoposide induction, caspase-3/MitoProbe detection) and yielded a similar 
lack of relationship between gene expression and function outcome (data not 
shown). 
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Figure 4.9: IFI27 transgene expression and mitochondrial membrane 
potential measurement. 
(A) MCS-control (top row) and IFI27 (bottom row) cell lines treated with 250 
ng/mL doxycycline for 4 hours, washed, etoposide-challenged (600 ng/mL), and 
assayed for apoptosis at 0, 1, 2, 4, and 24 hours post etoposide. 
MitoTrackerDilC1 (x-axis) shows cells with (Mito+) and without (Mito-) 
mitochondrial membrane potential. Annexin-V is shown on the y-axis. (B) The 
amount of Mito- cells as a percentage of the dual-fluorescent population is shown 
in MCS (circle) and IFI27 (square) cell lines after etoposide treatment over 24 
hours (n=3 internal replicates).  
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4.4 Discussion, limitations, and future directions 
 Expression of pro-apoptotic ISG12 genes (IFI27), which was observed in 
viremic patients in relation to elevated apoptosis (Chapter 2), did directly affect 
apoptosis regulation in the monocyte Monomac1 cell line in vitro. Thus, our data 
do not support the hypothesis that IFI27 over-expression would augment 
apoptosis outcome in vitro. The finding that single gene over-expression was not 
sufficient to impact apoptosis reinforces the interpretation that multiple genes (i.e. 
ISG12, Bcl2) induced with immune and viral pressure may account for regulation 
of apoptosis outcome in vivo (Chapter 2). 
 
 While our data do not support reports of functional links between 
expression IFI6 and IFI27 and mitochondrial membrane potential and apoptosis 
outcome (191-193, 228), experimental limitations and considerations may qualify 
our interpretation. First, while we demonstrated the induction of IFI27 RNA 
expression, we did not have suitable tools to confirm IFI27 protein expression. 
Second, our over-expression system does not preclude that gene knockdown in 
primary cells would not yield an apoptosis phenotype, as was demonstrated for 
Rb1 in primary HIV (-) monocytes (105). Third, the Monomac1 system, while 
chosen for control and reproducibility, introduces its own limitations in 
interpretation as a cancer cell line as oncogenic and pro-survival mutations and 
gene expression in a cell line may maintain viability to a point that cannot be 
overcome by over-expression of IFI27. 
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 This suggests follow-up work in primary monocytes and macrophages, 
while presenting challenges in gene delivery/expression and/or gene knockdown, 
may still be required to support or refute a positive impact of the genes described 
here. The association of monocyte ISG expression and apoptosis with HIV-1 
clinical metrics (established in chapter 2) would allow future studies to test the 
impact of IFI27 gene knockdown ex vivo. With optimized reagents and sufficient 
material, the impact of multiple candidate genes, highlighted in chapter 2, could 
be tested simultaneously. 
 
 In summary, we established Monomac1 cells lines for the doxycycline-
inducible expression of the apoptosis regulatory ISG12 genes, IFI6 and IFI27. 
Despite robust gene expression, we did not detect an impact on mitochondrial 
membrane potential or apoptosis outcome in this system. Our data suggest gene 
knockdown in primary monocytes may be a superior approach to address the 
mechanistic roles of IFI6 and IFI27 in the regulation of monocyte apoptosis. 
 
4.5 Materials 
 
4.5.1 Generation of inducible expression Monomac1 cell lines 
 IFI6 and IFI27 gene fragments were engineered with 5’ BamHI and 3’ 
Nhe1 restriction sites by PCR amplification from commercially obtained 
templates (Open Biosystems, clone ID 4654295 and 6495362 for IFI6 and IFI27) 
(Figure 4.1). The expression vectors pLU-EF1aL-rtTA3-iCherry (“helper plasmid”) 
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and pLU-TREmin-MCS-pGFP (“transducing plasmid”) were obtained from the 
Wistar Protein Expression Core. Gene fragments were ligated into the 
transducing plasmid and packaged in a VSV-delivery system for transduction 
(Wistar Protein Expression Core). We validated hPGK promoter activity 
(transducing plasmid) in the Monomac1 cell line (data not shown). The 
transduced cell lines (GFP, mCherry, MCS, IFI6, and IFI27) were sorted using 
the University of Pennsylvania Flow Cytometry Core (Figure 4.4A-B). 
Transduction for sort was scaled up to 4 million cells per single transduction and 
20 million cells per co-transduction. Gene expression was quantified by RT-PCR 
as done in Section 2.5.5. The primers used to detect Rb1, Mx1, IFI6, and IFI27 
(Figure 4.6) are detailed in Table 2.4. 
 
4.5.2 Apoptosis induction in transduced Monomac1 cell lines 
 Gene expression induction (doxycycline) and apoptosis challenge (CdCl2, 
etoposide) were optimized over multiple experiments. Experiments shown 
(Figure 4.8, 4.9) were conducted at 250-1000 ng/mL doxycycline and 0.6 to 6 
ug/mL etoposide. Caspase-3 and Annexin-V apoptosis detection antibodies (BD 
Biosciences) and MitoProbe DilC1 (ThermoFischer) were used per the 
manufacturers’ instructions. Samples were prepared for flow cytometry as in 
Section 2.5.6. Up to 100,000 events were analyzed on a 14-color LSR II (BD 
Biosciences). Flow cytometry data analysis was performed with FlowJo software 
(TreeStar). 
  
112 
 
Chapter 5: Conclusions and future directions 
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 5.3.2 Macrophages: Targeting tissue activation and apoptosis 
5.4 The role of HIV-1 disease state and viral/immunological pressures on 
monocyte apoptosis and monocyte/macrophage activation 
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5.1 Summary of main findings 
 In this dissertation, we focused on changes in apoptosis and activation in 
circulating monocytes during HIV-1 infection between low and high viremic 
patients and from pre-ART to ART suppressed conditions. The role of monocytes 
and macrophages in pathogenesis has been a focal point of the HIV research 
field for decades. However, investigations of the impact of HIV/SIV infection and 
virus-cell interactions on monocyte apoptotic outcome generated seemingly 
conflicting findings between in vitro studies, NHP models, and ex vivo patient 
cohort studies. Additionally, the description of HIV-1-associated microbial 
translocation has highlighted the presence and clinical significance of innate 
immune activation during HIV-1 infection. ART-mediated reversal of 
monocyte/macrophage activation during advanced infection has been 
understudied. To address the degree of monocyte apoptosis during high viremia, 
reversal of monocyte/macrophage activation during ART, and underlying 
mechanisms, we performed the following sets of experiments: 
1. We investigated ex vivo monocyte apoptosis from low and high viral 
load HIV (+) patients and performed hypothesis-generating RNA 
sequencing. 
2. We validated a shift in ex vivo monocyte apoptosis observed in high 
viral load conditions and investigated target gene expression in a 
broader HIV (+) cohort. 
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3. We examined the ART-mediated reversal of monocyte/macrophage 
activation during advanced HIV-1 infection in the presence and 
absence of CCR5 antagonism (Maraviroc). 
4. We tested the impact of the ISG12 genes IFI6 and IFI27 as a possible 
underlying mechanism regulating monocyte apoptosis in the context of 
HIV-1 infection. 
 
  We show, for the first time, that monocyte apoptosis is elevated in HIV (+) 
patients with viral loads above 40,000 HIV-1 copies/mL. The impetus to 
investigate apoptosis at high HIV-1 viral loads arose from the seemingly 
incongruous reports of anti-apoptotic impacts of HIV-1 infection on monocytes in 
vivo/ex vivo (103-105) and increased monocyte turnover and pro-apoptotic 
outcomes in SIV-NHP and in vitro HIV-1 studies (70, 71, 96). Furthermore, 
decreased monocyte viability may represent a source of monocyte dysfunction 
during advanced infection (97). Consequently, we initiated a pilot study to 
investigate CD4 T-cell and monocyte apoptosis and examine gene expression by 
RNA sequencing in HIV (+) patients with elevated viremia, and collected 
preliminary data suggesting apoptosis resistance observed during low, steady-
state viral load may shift to heightened apoptosis sensitivity at high viral loads. 
RNA sequencing analysis highlighted multiple gene families and genes, such as 
IFI6 and IFI27, for follow-up analysis that may regulate monocyte apoptosis 
during HIV-1 infection. 
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 It remained to be determined if a shift in monocyte apoptosis could be 
confirmed in a HIV (+) cohort spanning a broad spectrum of viral load and CD4 
count, and if detected, how a potential distribution of monocyte apoptosis 
sensitivity would be related to better-described monocyte/macrophage 
phenotypes during HIV-1 infection, including ISG expression (Section 1.4) and 
cell-associated and soluble markers of activation (Section 1.5). In a cross-
sectional cohort of HIV (+) individuals (n=35), we confirmed elevated constitutive 
and induced monocyte apoptosis in patients above 40,000 HIV-1 copies/mL and 
modeled the distribution of apoptosis outcome using observed changes in viral 
load and p53, ISG, and Bcl2 family gene expression (Chapter 2). Future studies 
in acute infection, elite controllers, and longitudinal ART cohorts (Chapter 3) may 
help determine the contributions of viremia, monocyte ISG expression, and 
innate immune activation in driving monocyte apoptosis outcome during HIV-1 
disease. 
 
 Next, we demonstrated differential reversal of cell-associated and soluble 
monocyte and macrophage activation biomarkers during ART in advanced HIV-1 
infection (Chapter 3). We monitored biomarkers of T-cell activation, 
monocyte/macrophage activation (cell-associated and soluble), monocyte ISG 
expression, and correlates of monocyte apoptosis outcome in an advanced HIV-
1 infection cohort (n=65) characterized by baseline CD4 count below 100 
cells/mm3 and viral suppression after 24 weeks ART. We also determined the 
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impact of CCR5 antagonism (ART versus ART + Maraviroc) on markers of T-cell 
and monocyte/macrophage activation and CCR5 expression in PBMC. 
 
 We did not detect an impact of Maraviroc on markers of T-cell activation or 
monocyte/macrophage activation, excluding a minor effect on CD4 T-cell 
activation, above ART alone. We did observe a higher percentage of CCR5 
expressing CD4 T-cells, CD8 T-cells, and monocytes in PBMC of the Maraviroc 
group during ART. As we did not examine tissue activation, as done elsewhere 
(217), we do not exclude a long-term impact of CCR5 antagonism on tissue 
damage, repair, and reconstitution, as should be a focus of future studies. 
 
 We show decreasing monocyte ISG expression is closely associated with 
decreased CD8 T-cell activation and greater relative reductions in cell-associated 
biomarkers of monocyte activation (CD14++CD16+ monocytes, CD163) compared 
to plasma soluble markers of monocyte/macrophage activation (sCD14, 
sCD163). The lack of greater change in both sCD14 and sCD163 after ART in 
advanced infection supports that microbial translocation and associated 
activation may be of greater concern in advanced infection independent of viral 
suppression. Our data highlight the benefits of viral suppression in advanced 
infection despite sub 200-CD4 reconstitution at 24 weeks and may provide 
monocyte immune reconstitution benchmarks, such as monocyte CD163 
expression, that can be monitored to inform CD4 recovery (Chapter 3). 
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 Lastly, we show over-expression of IFI6 or IFI27, candidate ISGs 
regulating apoptosis outcome and expressed in monocytes of patients with viral 
loads above 40,000 HIV-1 copies/mL, is insufficient to augment apoptosis 
outcome in a monocyte cell line in vitro (Chapter 4). This suggests single-gene 
over-expression fails to recapitulate the multi-family gene expression changes 
(Bcl2, p53, ISG) that may be required to affect apoptosis deregulation in vivo or 
simply cannot overcome the intrinsic transforming/survival pressures of the 
Monomac1 cell line used. An alternative hypothesis is the in the in vitro system 
used does not deliver a secondary stress or inflammatory signal required to 
observe an effect on apoptotic outcome. This is supported by the observation 
that monocyte-derived macrophages matured in the presence of HIV-1, GM-
CSF, and IL-6 are sensitized to LPS/IFN-γ induced apoptosis (96). 
 
 Findings presented in chapter 2 suggest the presence of at least two 
distinct phases of monocyte/macrophage apoptosis and activation during 
untreated infection (Figure 5.1): (1) below 40,000 HIV-1 copies/mL, characterized 
by increases in plasma sCD163 and the CD14++16+ monocyte subset, Rb1 
expression, and maintained viability (as described in (103-105)), and (2) above 
40,000 HIV-1 copies/mL, described here, characterized by increasing plasma 
sCD14 with viral load, high ISG expression, and elevated apoptosis. 
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Figure 5.1: Model of monocyte apoptosis and activation during chronic, 
untreated HIV-1 infection. 
Shown are clinical and monocyte apoptosis, ISG, and activation profiles with low 
(left) and high viremia (right) during chronic, untreated HIV-1 infection.  
 
 Our ART study indicates that monocyte/macrophage biomarkers of 
activation, often interpreted jointly, exhibit a differential reversal and may reflect 
distinct mechanisms of activation. These findings support a working model with a 
spectrum of reversal of monocyte/macrophage activation biomarkers (Figure 5.2, 
Chapter 3). At one end, we interpret categorical resolution of monocyte CD169 
expression by 12 weeks closely mirrors suppression of plasma viremia, followed 
by decreases in the remaining monocyte cell-associated markers and T-cell 
activation markers. On the other end of the spectrum, sCD14 and sCD163 may 
represent more clinically significant biomarkers of residual immune cross-talk and 
microbial translocation associated ligands (such as LPS) that may or may not be  
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Figure 5.2: Spectrum model of monocyte/macrophage activation 
biomarkers during ART in advanced HIV-1 infection. 
Shown is a simplified model of reversal of monocyte/macrophage activation 
markers during ART and potential viral and immunological drivers.  
 
 
efficiently reversed with ART in advanced infection. Finally, although these 
findings represent independent cross-sectional and longitudinal studies, we can 
supplement our initial model to generate a simplified representation of the 
plasticity of monocyte apoptosis and activation with HIV-1 infection state (Figure 
5.3). 
 
 Taken together, our work demonstrates monocyte/macrophage apoptosis 
outcomes and activation markers are a complex reflection of infection state and 
the associated collection of underlying host and pathogen pressures. 
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Figure 5.3: Model of monocyte/macrophage apoptosis and activation 
relative to HIV-1 infection state. 
Shown is an extension of Figure 5.1 to include impact of ART-mediated viral 
suppression (right) in addition to low viremia (left) and high viremia (center) 
during untreated, chronic HIV-1 infection.  
 
 
5.2 Context 
 
5.2.1 “High viremia” monocytes apoptosis: ISG expression and innate 
activation, common denominators 
 Our description of elevated apoptosis in monocytes from HIV (+) patients 
with viral loads above 40,000 HIV-1 copies/mL highlights underlying themes in 
previous monocyte apoptosis studies in NHP-SIV, HIV, and in vitro systems (70, 
71, 96, 99). Elevated “off-ART” constitutive apoptosis (compared to HIV (-) 
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individuals) was observed in a small but broad viral load cohort (n=10, mean viral 
load = 94,000 HIV-1 copies/mL, range = 6,000-300,000 HIV-1 copies/mL) (99). 
Elevated STAT1 protein expression in the “off-ART” group and the association of 
STAT1 expression with apoptosis outcome in this group align with our findings of 
elevated ISG expression and monocyte apoptosis in high viral load patients 
within our HIV (+) cohort. 
 
 A pro-apoptotic impact of HIV-1 in vitro has been demonstrated when 
monocytes are differentiated in the presence of HIV-1 (Bal), GM-CSF, and IL-6, 
sensitizing them to activation-induced (IFN-γ/LPS) apoptosis (compared to GM-
CSF, IL-6 conditions alone) (96). Although we did not measure plasma IL-6 and 
LPS in our study, plasma sCD14 was associated with viral load (Figure 2.11C), 
and elevated plasma IL-6 in both viremic and ART-suppressed patients 
(compared to HIV (-) individuals) has been described elsewhere (35). We 
interpret this in vitro system may mimic inflammatory and activation pressures 
present during high HIV-1 viremia in vivo. 
 
 Our data join an increasing body of evidence suggesting that high HIV/SIV 
viral load and low CD4 count may be associated with changes in monocyte 
functional responses, including greater monocyte turnover (associated with 
plasma sCD163) (70, 71), tissue migration (70, 71, 94), and macrophage 
apoptosis in tissue (70). This study complements studies in SIV-infected 
macaques (using in vivo BrdU labeling) in which disease progression (i.e. high 
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viral load) was associated with increased monocyte turnover, associated with 
higher tissue apoptosis (70). Overall, our data suggest as viral load rises, added 
TLR-mediated activation and/or ISG induction may override existing anti-
apoptotic mechanisms, resulting in higher monocyte turnover. 
 
5.2.2 Reversal of monocyte/macrophage activation during advanced 
infection: Filling in the picture 
 First described almost a decade ago (86), microbial translocation and 
associated immune activation during HIV-1 infection have been established as a 
strong predictor of mortality (91, 92) and are associated with CNS pathogenesis 
(77) and immune dysfunction (211). Incomplete resolution of 
monocyte/macrophage activation after ART described here (advanced infection) 
and elsewhere (Table 3.1) supports persistence of innate activation despite viral 
suppression. 
 
 Here we show reversal of activated monocyte subsets and markers of ISG 
expression despite nadir CD4 counts below 100 cells/mm3, highlighting early 
immunological benefits of ART in advanced infection. Nonetheless, the 
persistence of sCD14 during ART as an indicator of lasting microbial 
translocation supports the investigation of interventions targeting innate 
activation. Recently, two clinical trials targeting vascular inflammation in HIV (+) 
cohorts demonstrated clinical benefit regarding reversal of innate immune 
activation. First, the integrase inhibitor, Elvitegravir reduced sCD14 beyond 
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standard ART alone (238). Second, addition of Rosuvastatin to a standard ART 
regimen reduced sCD14, the non-classical (CD14+CD16++) monocyte subset, 
plasma CXCL10, and CD4 and CD8 T-cell activation over placebo (239, 240). 
Our data demonstrating elevated innate immune activation with increasing viral 
load (Chapter 2) and the persistence of innate activation despite suppressive 
ART in advanced infection (Chapter 3), reinforce the significance of the 
development of these next generation ART strategies. 
 
5.3 Future Directions 
 
5.3.1 Elucidating immune and viral pressures driving monocyte apoptosis 
 The HIV (+) cohort in this thesis with elevated monocyte apoptosis at high 
viral loads (Chapter 2) represents HIV-1 disease with high viremia, evidence of 
innate immune activation and microbial translocation (Figure 2.11, 2.12), and ISG 
expression (Table 2.4, Figure 2.13) (absent symptomatic opportunistic infection). 
The impact of ART initiated from high viral load on monocyte apoptosis remains 
to be described directly. Our data (Chapter 3) suggest ART-mediated viral 
suppression and ISG reversal proceed reversal of TLR-mediated activation, 
allowing one to investigate the impact of residual TLR-mediated activation on 
monocyte apoptosis in the absence of viremia and ISG expression. Interestingly, 
cross-sectional data from our lab show induced monocyte apoptosis is higher in 
ART-patients than a low level viremic cohort (median viral load = 13,468 HIV-1 
copies/mL) (and evidence loss off anti-apoptotic Rb1 activity with ART) (105). 
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Conversely, characterization of monocyte apoptosis in patients during acute 
infection would evaluate the impact of peak viremia and ISG expression absent 
established microbial translocation (86). 
 
5.3.2 Macrophages: Targeting tissue activation and apoptosis 
 Recently, attention has focuses on HIV-1 tissue reservoirs as a significant 
challenge to the cure initiative, within which macrophages play a major role (49, 
241, 242). The degree to which monocyte apoptosis (Chapter 2) and activation 
phenotypes (Chapter 2, Chapter 3) extend to tissue macrophages have 
significant implications regarding pathogenesis and viral reservoirs. 
 
 While macrophage apoptosis has been described in CNS and lymph 
nodes during SIV NHP infection (70, 95), direct measurements during HIV-1 
infection have been limited. Future studies should take advantages of lymph 
node and rectal biopsy techniques to determine the degree of macrophage 
apoptosis in tissue during viremic and ART-suppressed HIV-1 infection. Such 
studies would inform potential contributions of macrophage apoptosis/dysfunction 
to gut epithelial barrier damage (88, 93, 94) and the development of opportunistic 
infection. 
 
 On a related note, tissue characterization of macrophage activation may 
similarly inform on gut epithelial barrier damage and microbial translocation (88, 
93, 94). Additionally, these studies could determine if retention of tissue 
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macrophage activation is associated with, and may contribute to, the size and 
persistence of the HIV-1 tissue reservoir in both CD4 T-cells and macrophages. 
This will inform the relationship between innate activation in tissue and viral 
persistence and may highlight mechanisms important in targeting the HIV-1 
tissue reservoir. 
 
5.4 The role of HIV-1 disease state and viral/immunological pressures on 
monocyte apoptosis and monocyte/macrophage activation 
 The work presented in this dissertation demonstrates the plasticity of 
monocyte/macrophage apoptosis and activation markers and their association 
with the stage of HIV-1 infection and infection-associated pressures (viremia, ISG 
expression, and microbial translocation). Previous studies and work presented 
here suggest the apoptotic fate of monocytes may represent a barometer of 
immune stress manifest during infection in vivo. Additionally, the spectrum of 
reversal of different biomarkers of monocyte/macrophage activation with ART 
may be useful in informing both immune reconstitution and the persistence of 
microbial translocation and associated activation. 
 
 Understanding the immunological and viral pressures driving functional 
changes in monocytes and macrophages will be vital in the targeting and 
reversing HIV-1 associated innate immune activation. 
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